METHOD OF PROVIDING NOVEL DNA SEQUENCES

Abstract: The present invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, comprising the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv). Further, the invention also relates novel DNA sequences provided according to the method of the invention and polypeptides with an activity of interest encoded by said novel DNA sequences of the invention.

Description: Title: Method of providing novel DNA sequences FIELD OP THE INVENTION The present invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, novel DNA sequences provided according to the method of the invention, polypeptides with an activity of interest encoded by novel DNA sequences of the invention. BACKGROUND OF THE INVENTION The advent of recombinant DNA techniques has made it possible to select single protein components with interesting properties and produce them on a large scale. This represents an improvement over the previously employed production process using microorga¬ nisms isolated from nature and producing a mixture of proteins which would either be used as such or separated after the produc¬ tion step. Since the traditional methods were rather time-consuming, more rapid and less cumbersome methods were developed. A such technique is described in WO 93/11249 (Novo Nordisk A/S) . The method described in WO 93/11249 comprises the steps of: a) cloning, in suitable vectors, a DNA library from an organism suspected of producing one or more proteins of interest; b) transforming suitable yeast host cells with said vectors; c) culturing the host cells under suitable conditions to express any protein of interest encoding by a clone in the DNA library; and d) screening for positive clones by determining any activity of a protein expressed in step c) . According to this method it is necessary to prepare a DNA library, comprising complete genes encoding polypeptides with activities of interest. Such a library has traditionally been made on mRNA isolated from micro-organisms which has been cultivated and isolated. As it is only possible with known methods to cultivate about 2% of the microorganisms known today (i.e. cultivable microorga¬ nisms) , genes encoding polypeptides from a huge number of microorganisms (i.e. un-cultivable microorganisms) are generally difficult to identify and clone on the basis of screening tech¬ nologies used today, such as the above mentioned. SUMMARY OF THE INVENTION It is the object of the present invention to provide a method for providing a novel DNA sequence encoding a polypeptide with an activity of interest from micro-organisms without having to cul¬ tivate and isolate said micro-organisms. In the first aspect the invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, comprising the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3* structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv) Further, the invention also relates novel DNA sequences provided according to the method of the invention and polypeptides with an activity of interest encoded by said novel DNA sequences of the invention. BRIEF DESCRIPTION OF THE DRAWING Figure 1 shows the cloning strategy of novel hybrid enzyme sequences. a is an exact N-terminal consensus primer a rc is the reverse and complement primer to a b is a degenerated homologous N-terminal primer c is a degenerated homologous C-terminal primer d is an exact C-terminal consensus primer d rc is a reverse and complement of d f is an exact reverse and complement C-terminal primer extended with a sequence which includes a Sail restriction recognition site. e is an exact N-terminal primer extended with a sequence which includes an EcoRI restriction recognition site. 1. (in figure 1) PCR with primers ab and cd to amplify unknown core genes with an activity of interest. PCR with primers e and a rc to obtain the N-terminal part of the known gene. PCR with primers d rc and f to obtain the C-terminal part of the known gene. 2. (in figure 1) SOE-PCR with primers e and f to link the unknown core gene sequence with the known N- and C-terminal gene sequences and introduction of EcoRI and Sail restriction recognition sites. 3. Restriction enzyme digestion followed by ligation of the novel sequence into an expression vector and transformation into a host cell. Screening of clones expressing the produced gene product with the activity of interest. Figure 2 shows a part of an alignment of prokaryote xylanases belonging to glycosyl hydrolases family 11. Figure 3 shows an alignment of the translated DNA sequences of Pulpzyme® (SEQ ID NO 2) and the novel gene sequence found in soil, respectively. Figure 4 shows a schematically a novel hybrid gene provided according to the invention. Part A and Part C are the known sequences linked to the unknown Part B. Using Pulpzyme® (SEQ ID NO 1) as the starting sequence: "1" indicated the first nucleotide of the novel hybrid gene provided according to the invention, "433" and "631" the start and end of the part constituted by the unknown gene sequence and "741" the last nucleotide of the novel hybrid gene sequence. DEFINITIONS Prior to discussing this invention in further detail, the following terms will first be defined. "Homology of DNA sequences or polynucleotides" In the present context the degree of DNA sequence homology is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Gene¬ tics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-453) . "Homologous": The term "homologous" means that one single- stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridiza¬ tion may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later (vide infra) . Using the computer program GAP (vide supra) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, it is in the present context believed that two DNA sequences will be able to hybridize (using low stringency hybridization conditions as defined below) if they mutually exhibit a degree of identity preferably of at least 70%, more preferably at least 80%, and even more preferably at least 85%. "heterologous": If two or more DNA sequences mutually exhibit a degree of identity which is less than above specified, they are in the present context said to be "heterologous". "Hybridization:" Suitable experimental conditions for determining if two or more DNA sequences of interest do hybri¬ dize or not is herein defined as hybridization at low stringency as described in detail below. A suitable experimental low stringency hybridization pro¬ tocol between two DNA sequences of interest involves pre- soaking of a filter containing the DNA fragments to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 μg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a concentration of lOng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) Anal . Biochem . 132:6-13), 32 P-dCTP-labeled (specific activity > 1 x 10 9 cpm/μg ) probe (DNA sequence) for 12 hours at ca. 45°C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at least 50°C, more preferably at least 55°C, and even more preferably at least 60°C (high stringency) . Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a x-ray film. "Alignment": The term "alignment" used herein in connection with a alignment of a number of DNA and/or amino acid sequences means that the sequences of interest is aligned in order to identify mutual/common sequences of homology/identity between the sequences of interest. This procedure is used to identify common "conserved regions" (vide infra) , between sequences of interest. An alignment may suitably be determined by means of computer programs known in the art, such as ClusterW or PILEUP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-453). "Conserved regions:" The term "conserved region" used herein in connection with a "conserved region" between DNA and/or amino acid sequences of interest means a mutual common sequence region of the sequences of interest, wherein there is a relatively high degree of sequence identity between the sequences of interest. In the present context a conserved region is preferably at least 10 base pairs (bp)/ 3 amino acids(a.a), more preferably at least 20 bp/ 7 a.a., and even more preferably at least 30 bp/ 10 a.a.. Using the computer program GAP (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-453) (vide supra) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the degree of DNA sequence identity within the conserved region is preferably of at least 80%, more preferably at least 85%, more preferably at least 90%, and even more preferably at least 95%. "Sequence overlap extension PCR reaction (SOE-PCR)": The term "SOE-PCR" is a standard PCR reaction protocol known in the art, and is in the present context defined and performed according to standard protocols defined in the art ("PCR A practical approach" IRL Press, (1991) ) . "primer": The term "primer" used herein especially in connection with a PCR reaction is an oligonucleotide (especially a "PCR-primer") defined and constructed according to general standard specification known in the art ("PCR A practical ap¬ proach" IRL Press, (1991)). "A primer directed to a sequence:" The term "a primer directed to a sequence" means that the primer (preferably to be used in a PCR reaction) is constructed so it exhibits at least 80% degree of sequence identity to the sequence part of interest, more preferably at least 90% degree of sequence identity to the sequence part of interest, which said primer consequently is "directed to". The primer is designed in order to specifically anneal at the region at a given temperature it is directed to¬ wards. Especially identity at the 3' end of the primer is essen¬ tial for the function of the polymerase, i.e. the ability of a polymerase to extend the annealed primer. "Polypeptide" Polymers of amino acids sometimes referred to as protein. The sequence of amino acids determines the folded conformation that the polypeptide assumes, and this in turn determines biological properties such as activity. Some polypeptides consist of a single polypeptide chain (monomeric) , whilst other comprise several associated polypeptides (multime- ric) . All enzymes and antibodies are polypeptides. "Enzyme" A protein capable of catalysing chemical reactions. Specific types of enzymes are a) hydrolases including amylases, cellulases and other carbohydrases, proteases, and lipases, b) oxidoreductases, c) Ligases, d) Lyases, e) Isomerases, f) Transferases, etc. Of specific interest in relation to the present invention are enzymes used in detergents, such as proteases, lipases, cellulases, amylases, etc. "known sequence" is the term used for the DNA sequences of which the full length sequence has been sequenced or at least the sequence of one conserved regions is known. "unknown sequence" is the term used for the DNA sequences amplified directly from uncultivated micro-organisms comprised in e.g. a soil sample used as the starting materia. "Full length DNA sequence" means a structural gene sequence encoding a complete polypeptide with an activity of interest. "un-cultivated" means that the micro-organism comprising the unknown DNA sequence need not be isolated (i.e. to provide a population comprising only identical micro-organisms) before amplification (e.g. by PCR) . The term "an activity of interest" means any activity for which screening methods is known. The term "un-cultivable micro-organisms" defined micro-orga¬ nisms which can not be cultivated according to methods know in the art. The term "DNA" should be interpreted as also covering other polynucleotide sequences including RNA. The term "linking" sequences means effecting a covalent binding of DNA sequences. The term "hybrid sequences" means sequences of different origin merged together into one sequence. The term "structural gene sequence" means a DNA sequence coding for a polypeptide with an activity. The term "natural occurring DNA" means DNA, which has not been subjected to biological or biochemical mutagenesis. By biological mutagenesis is meant "in vivo" mutagenesis, i.e. propagation under controlled conditions in a living organism, such as a "mutator" strain, in order to create genetic diversity. By biochemical mutagenesis is meant "in vitro" mutagenesis, such as error-prone PCR, oligonucleotide directed site-specific or random mutagenesis etc. DETAILED DESCRIPTION OF THE INVENTION It is the object of the present invention to provide a method for providing novel DNA sequences encoding polypeptides with an activity of interest from micro-organisms without having to cultivate said micro-organisms. The inventors of the present invention have found that PCR- screening using primers designed on the basis of known homologous region, such as conserved regions, can be used for providing novel DNA sequences. Despite the fact that known homologous regions, such as conserved regions, are used for primer designing a vast number of unknown DNA sequences have been provided. This will be described in the following and illustrated in the Examples. The DNA sequences provided are full length hybrid structural gene sequences encoding complete polypeptides with an activity of interest made up of one unknown sequence and one or two known sequences. According to the invention it is essential to identify at least two homologous regions, such as conserved regions, in known gene sequences with the activity of interest. One or two selected known structural gene sequence(s) is(are) used as templates (i.e. as starting sequence(s) ) for finding and constructing novel DNA structural gene sequences with an activity of interest. Said homologous regions, such as conserved regions, can be identified by alignment of polypeptides with the activity of interest and may e.g. be made by the computer program ClustalW or other similar programs available on the market. One known structural gene as the starting sequence In the case of using one known structural gene sequence as the starting sequence it will typically be comprised in a plasmid or vector or the like. A part of the sequence between the two identified homologous regions, such as conserved regions, are deleted to avoid contamination by the wild-type structural gene. The known DNA sequence, with the homologous regions, such as conserved regions, placed at the ends, are linked to an unknown DNA sequence amplified directly or indirectly from a sample comprising micro-organisms. The identified homologous regions, such as conserved regions, must have a suitable distance from each other, such as 10 or more base pairs in between. It is preferred to use homologous regions, such as conserved regions, placed in each end of the known structural full length gene. However, if knowledge about a specific function (e.g. active site) of a domain (i.e. part of the structural gene sequence) is available it may be advantageous to used conserved regions placed in proximity of and on each side said domain as basis for the PCR amplification to provide novel DNA sequences according to the invention which will be described below in details. Two known genes as starting sequences In the case of using two known structural genes as the stating sequences at least one homologous region, such as conserved region, should be identified in each of the two sequences within the polypeptide coding region. In both case (i.e. one or two known genes as starting sequences) the homologous regions, such as conserve regions, should preferably be situated at each end of the structural gene(s) (i.e. the sequences encoding the N-terminal end (i.e. named Part A on figure 4) and the C-terminal end, respectively (i.e. named Part C on figure 4) of the known part of the hybrid polypeptide In the first aspect the invention relates to a method for providing novel DNA sequences encoding polypeptides with an activity of interest comprises the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv) In step i) the part between the corresponding homologous regions, such as conserved regions, of the unknown structural gene are amplified. In an embodiment the PCR amplification in step i) is performed using naturally occurring DNA or RNA as template. In anither embodiment the micro-organism has not been subjected to "in vitro" selection. The PCR amplification may be performed on a sample containing DNA or RNA from un-isolated micro-organisms. According to the invention no prior knowledge about the unknown sequence is required. In an embodiment of the invention said 5' and 3 ' structural gene sequences originate from two different known structural gene sequences encoding polypeptides having the same activity or related activity. The 5' structural gene sequence and the 3 ' structural gene sequence may also originate from the same known structural gene encoding a polypeptide with the activity of interest or from two different known structural gene sequences encoding polypeptides having different activities. In the latter case it is preferred that at least one of the starting sequences originates from a known structural gene sequence encoding a polypeptide with the activity of interest. In a preferred embodiment of the method of the invention the known structural gene is situated in a plasmid or a vector. In said case the method comprises the following steps: i) PCR amplification of DNA from micro-organisms with PCR primers being homologous to conserved regions of a known gene encoding a polypeptide with an activity of interest, ii) cloning the obtained PCR product into a gene encoding a polypeptide having said activity of interest, where said gene is not identical to the gene from which the PCR product is obtained, which gene is situated in an expression vector, iii) transforming said expression vector into a suitable host cell, iiia) culturing said host cell under suitable conditions, iv) screening for clones comprising a DNA sequence originated from the PCR amplification in step i) encoding a polypeptide with said activity of interest or a related activity, v) isolating the DNA sequence identified in step iv) . According to this embodiment one known structural gene sequence is used as the starting sequence. It is to be understood that the PCR product obtained in step i) is cloned into a known gene where a part of the DNA sequence, between the conserved regions, is deleted (i.e. cut out) or in an other way substituted with the PCR product. The deleted part of the known gene comprised in the vector may have any suitable size, typically between 10 and 5000 bp, such as from between 10 to 3000 bp. A general problem is that, when amplifying DNA sequences encoding polypeptides with an activity by PCR, the obtained PCR product (i.e. being a part of an unknown gene) does not normally encode a polypeptide with the desired activity of interest. Therefore, according to the invention the complete full length structural gene, encoding a functional polypeptide, is provided by cloning (i.e. by substituting) the PCR product of the unknown structural gene into the known gene situated on the expression vector. It should be emphasised that the DNA mentioned in step i) , to be PCR amplified, need not to comprise a complete gene encoding a functional polypeptide. This is advantageous as only a smaller region of the DNA of the micro-organism(s) in question need to be amplified. The novel DNA sequences obtained according to the invention consist of the PCR product merged or linked into the known gene, having a number of nucleotides between the conserved regions deleted. The PCR product is inserted into the known gene between the two ends of the cut open vector by overlapping homologous regions of about 10 to 200 bp at each end of the vector. The resulting novel hybrid DNA sequences constitute complete full length genes comprising the PCR product and encodes a polypeptide with the activity of interest. It is to be understood that it is not absolutely necessary to delete a part of the known gene sequence. However, if a part of the known gene sequence is not deleted re-ligation results in that the wild-type activity of the known gene is regained and thus give a high number of wild-type background clones, which would make the screening procedure more time consuming and cumbersome. The PCR amplification in step i) can be performed on both cultivable and uncultivable micro-organisms by directly or indirectly amplification of DNA from the genomic material of the micro-organisms in the environment (i.e. directly or indirectly from the sample taken) . The micro-organisms The micro-organisms from which the unknown DNA sequences are derived may be micro-organisms which cannot today be cultivated. This is possible as the DNA sequences can be amplified by PCR without the need first to cultivate and isolate the micro¬ organisms comprising the unknown DNA sequence(s) . It is however to be understood that the method of the invention can also be used for providing novel DNA sequences derived from micro-organisms which can be cultivated. Therefore the method of the invention can be performed on both cultivable and un-cultivable organisms as the micro-organisms in question do not, according to the method of the invention, need to be cultivated and isolated from, e.g. the soil sample, comprising micro-organisms. Starting material The starting material, i.e. the sample comprising micro¬ organisms with the target unknown DNA sequences, may for instance be an environmental samples of plant or soil material, animal or insect dung, insect gut, animal stomach, a marine sample of sea or lake water, sewage, waste water, etc., comprising one or, as in most case, a vast number of different cultivable and/or un- cultivable micro-organisms. If the genomic material of the micro-organisms are readily accessible the PCR amplification may be performed directly on the sample. In other cases a pre-purification and isolation procedure of the genomic material is needed. Smalla et al. (1993), J. Appl. Bacteriol 74, p. 78-85; Smalla et al. (1993), FEMS Microbiol Ecol 13, p. 47-58, describes how to extract DNA directly from micro-organisms in the environment (i.e. the sample). Borneman et al. (1996) , Applied and Environmental Microbiology, 1935-1943, describes a method for extracting DNA from soils. A commercially available kit for isolating DNA from environmental samples, such as e.g. soils, can be purchased from BIO 101 under the tradename FastDNA® SPIN Kit. Seamless™ Cloning kit (cataloge no. Stratagene 214400) is a commercial kit suitable for cloning of any DNA fragment into any desired location e.g. a vector, without the limitation of naturally occurring restriction sites. PCR amplification of DNA and/or RNA of micro-organisms in the environment is described by Erlich, (1989) , PCR Technology. Principles and Applications for DNA Amplification, New York/London, Stockton Press; Pillai, et al., (1991), Appl. Environ. Microbiol, 58, p. 2712-2722) Other methods for PCR amplifying microbial DNA directly from a sample is described in Molecular Microbial Ecology Manual, (1995), Edited by Akkermans et al.. A suitable method for microbial DNA from soil samples is described by Jan Dirk van Elsas et al., (1995), Molecular Microbial Ecology Manual 2.7.2, p. 1-10. Stein et al., (1996), J. Bacteriol., Vol. 178, No. 2, p. 591- 599, describes a method for isolating DNA from un-cultivated prokaryotic micro-organisms and cloning DNA fragments therefrom. The PCR primers being homologous to conserved regions of the known gene encoding a polypeptide with an activity of interest are synthesized according to standard methods known in the art (see for instance EP 684 313 from Hoffmann-La Roche AG) on the basis of knowledge to conserved regions in the polypeptide with the activity of interest. Said PCR primers may be identical to at least a part of the conserved regions of the known gene. However, said primers may advantageously be synthisized to differ in one or more positions. Further, a number of different PCR primers homologous to the conserved regions may be used at the same time in step i) of the method of the invention. The cultivable or uncultivable micro-organisms may be both prokaryotic organisms such as bacteria, or eukaryotic organisms including algae, fungi and protozoa. Examples of un-cultivable organisms include, without being limited thereto, extremophiles and plantonic marine organisms etc. The group of cultivable organisms include bacteria, fungal organisms, such as filamentous fungi or yeasts. In the case of using DNA from cultivable organisms the PCR amplification in step i) may be performed on one or more polynucleotides comprised in a vector, plasmid or the like, such as on a cDNA library. Specific examples of "an activity of interest" include enzyma- tic activity and anti-microbial activity. In a preferred embodiment of the invention the activity of interest is an enzymatic activity, such as an activity selected from the group comprising of phosphatases oxidoreductases (E.C. 1), transferases (E.C. 2); hydrolases (E.C. 3), such as esterases (E.C. 3.1), in particular lipases and phytase; such as glucosidases (E.C 3.2), in particular xylanase, cellulases, hemicellulases, and amylase, such as peptidases (E.C. 3.4), in particular proteases; lyases (E.C. 4); isomerases (E.C 5); ligases (E.C. 6) . The host cell used in step iii) may be any suitable cell which can express the gene encoding the polypeptide with the activity of interest. The host cells may for instance be a yeast, such as a strain of Saccharomyces , in particular Saccharomyces cerevisiae , or a bacteria, such as a strain of Bacillus , in particular of Bacillus εubtiliε , or a strain Escherichia coli . Clones found to comprise a DNA sequence originated from the PCR amplification in step i) may be screened for any activity of interest. Examples of such activities include enzymatic activity, anti-microbial activity or biological activities. The polypeptide with the activity of interest may then be tested for a desired performance under specific conditions and/or in combination with e.g. chemical compounds or agent. In the case where the polypeptide is an enzyme e.g. the wash performance, textile dyeing, hair dyeing or bleaching properties, effect in feed or food may be assayed to identify polypeptides with a de¬ sired property. Identification of conserved regions of prokarvote xylanases Figure 2 shows an alignment of prokaryote xylanases from the family 11 of glycosyl hydrolases (B. Henrissat, Biochem J, 280:309-316 (1991)). There are several region where the amino acids are identical or almost identical, i.e. conserved regions. Examples of homologous regions or conserved regions in prokaryotic xylanases from family 11 of glycosyl hydrolases (B. Henrissat, (1991), Biochem J 280:309-316) are the sequence "DGGTYDIY" (SEQ ID NO 3) position 145-152, "EGYQSSG" (SEQ ID NO. 4) position 200-206 in the upper polypeptide shown in figure 2. Based on e.g. said regions degenerated PCR primers can be designed. These degenerated PCR primers can amplify unknown DNA sequences coding for polypeptides (i.e. referred to as PCR products below) which are homologous to the known polypeptide(s) in question (i.e. SEQ ID NO 2) flanked by the conserved regions. The PCR products obtained can be cloned into a plasmid and sequenced to check if they contain conserved regions and are homologous to the known structural gene sequence(s). A homologous PCR product is however not a guarantee that the sequence code for a part of a polypeptide having the desired activity of interest. Therefore, according to the method of the invention one or more steps selecting DNA sequences encoding polypeptides having the activity of interest follow the construction of the novel hybrid DNA sequences. The unknown DNA sequences When method of the invention is performed on DNA from samples of uncultivated organisms it is advantageous to screen for gene products with the activity of interest. A suitable method for doing this is to link the PCR products with a 5' sequence upstream the first conserved region DNA sequence and the 3 ' sequence downstream the second consen¬ sus, respectively, from the known gene sequence. The product of the unknown gene sequence linked to an N- terminal and C-terminal part of a known gene product is then screened for the activity of interest. The N-terminal and C-terminal parts can originate from the same gene product but it is not a prerequisite for activity. The N-terminal and C-terminal parts may also originate from different gene products as long as they originate from the same polypeptide family e.g. the same glycosyl hydrolases. A method to link the unknown gene sequence with the known sequences is to clone the PCR product into a known gene, encoding a polypeptide having the activity of interest, which have had the sequences between the conserved regions removed. Another method is merging the PCR product, the N-terminal part and the C-terminal part by SOE-PCR (splicing by overlap extension PCR) e.g. as shown in figure 1 and described in detail in Example 1. Other methods known in the art may also be used. In a second aspect the invention relates to a novel DNA sequence provided by the method of the invention and the polypeptide encoded by said novel DNA sequence. MATERIALS AND METHODS Pulpzyme® is a xylanase derived from Bacillus sp. AC13, NCIMB No. 40482. and is described in WO 94/01532 from Novo Nordisk A/S AZCL Birch xylan (MegaZyme, Australia) . Plasmids: The Aspergillus expression vector pHD414 is a derivative of the plasmid p775 (described in EP 238 023) . The construction of pHD414 is further described in WO 93/11249. The 43 kD EG V endoglucanase cDNA from H. insolens (disclosed in WO 91/17243) is cloned into pHD414 in such a way that the endoglucanase gene is transcribed from the TAKA-pro- moter. The resulting plasmid is named pCaHj418. Kits QIAquick PCR Purification Kit Protocol Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) AmpliTaq Gold polymerase (Perkin-Elmer, USA) Micro-organisms Bacteria electromax DH10B E. coli cells (GIBCO BRL) Fungal micro-organisms: Cylindrocarpon sp. : Isolated from marine sample, the Bahamas Classification: Ascomycota, Pyrenomycetes, Hypocreales unclassified Fusarium anguioides Sherbakoff IFO 4467 Classification: Ascomycota, Pyrenomycetes, Hypocreales, Hypo- creaceae Gliocladium catenulatum Gillman & Abbott CBS 227.48 Classification: Ascomycota, Pyrenomycetes, Hypocreales, Hypo- creaceae Humicola nigreεcens Omvik CBS 819.73 Classification: Ascomycota, Pyrenomycetes, Sordariales, (fam. unclassified) Trichothecium roseum IFO 5372 Plates LB-ampicillin plates: 10 g Bacto-tryptone, 5 g Bacto yeast extract, 10 g NaCl, in 1 litre water, 2% agar 0.1% AZCL Birch xylan, 50 microg/ml ampicillin. Eguipment Applied Biosystems 373A automated sequencer PCR Amplification All Polymerase Chain Reactions is carried out under stan- dard conditions as recommended by Perkin-Elmer using AmpliTaq Gold polymerase. Isolation of Environmental DNA DNA is isolated from an environmental sample using FastDNA® SPIN Kit for Soil according to the manufacture's instructions. Methods used in Example 3 Strains and growth conditions The fungal strains listed above, were streaked on PDA plates containing 0.5 % Avicel, and examined under a microscope to avoid obvious mistakes and contaminations. The strains were cultivated in shake flasks (125 rpm and 26 °C) containing 30ml PD medium (to initiate the growth) and 150ml of BA growth medium for cellulase induction. The production of cellulases in culture supematants (typically after 3, 5, 7 and 9 days of growth) was assayed u- sing 0.1 % AZCl-HE-cellulose in a plate assay at pH 3, pH 7 and pH 10. The mycelia were harvested and stored at - 80°C Preparation of RNase-free glassware, tips and solutions All glassware used in RNA isolations were baked at + 250°C for at least 12 hours. Eppendorf tubes, pipet tips and plastic columns were treated in 0.1 % diethylpyrocarbonate (DEPC) in EtOH for 12 hours, and autoclaved. All buffers and water (except Tris-containing buffers) were treated with 0.1 % DEPC for 12 hours at 37°C, and autoclaved. Extraction of total RNA The total RNA was prepared by extraction with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M CsCl cushion [Chirgwin, (1979) Biochemistry 18, 5294-5299] using the following modifications. The frozen mycelia was ground in liquid N2 to fine powder with a mortar and a pestle, followed by grinding in a precooled coffee mill, and immedi¬ ately suspended in 5 vols of RNA extraction buffer (4 M GuSCN, 0.5 % Na-laurylsarcosine, 25 mM Na-citrate, pH 7.0, 0.1 M β- mercaptoethanol) . The mixture was stirred for 30 min. at RT° and centrifuged (20 min., 10 000 rpm, Beckman) to pellet the cell debris. The supernatant was collected, carefully layered onto a 5.7 M CsCl cushion (5.7 M CsCl, 0.1 M EDTA, pH 7.5, 0.1 % DEPC; autoclaved prior to use) using 26.5 ml supernatant per 12.0 ml CsCl cushion, and centrifuged to obtain the total RNA (Beckman, SW 28 rotor, 25 000 rpm, RT°, 24h) . After centrifuga¬ tion the supernatant was carefully removed and the bottom of the tube containing the RNA pellet was cut off and rinsed with 70 % EtOH. The total RNA pellet was transferred into an Eppen- dorf tube, suspended in 500 μl TE, pH 7.6 (if difficult, heat occasionally for 5 min at 65 °C) , phenol extracted and precipi¬ tated with ethanol for 12 h at -20°C (2.5 vols EtOH, 0.1 vol 3M NaAc, pH 5.2). The RNA was collected by centrifugation, washed in 70 % EtOH, and resuspended in a minimum volume of DEPC-DIW. The RNA concentration was determined by measuring OD 260/280. Isolation of polv(A)+RNA The poly(A)+ RNAs were isolated by oligo(dT)-cellulose af¬ finity chromatography [Aviv, (1972) , Proc. Natl. Acad. Sci. U.S.A. 69, 1408-1412]. Typically, 0.2 g of oligo(dT) cellulose (Boehringer Mannheim, Germany) was preswollen in 10 ml of 1 x column loading buffer (20 mM Tris-Cl, pH 7.6, 0.5 M NaCl, 1 mM EDTA, 0.1 % SDS), loaded onto a DEPC-treated, plugged plastic column (Poly Prep Chromatography Column, Bio Rad) , and equili¬ brated with 20 ml 1 x loading buffer. The total RNA (1-2 mg) was heated at 65 °C for 8 min. , quenched on ice for 5 min, and after addition of 1 vol 2 x column loading buffer to the RNA sample loaded onto the column. The eluate was collected and reloaded 2-3 times by heating the sample as above and quenching on ice prior to each loading. The oligo(dT) column was washed with 10 vols of 1 x loading buffer, then with 3 vols of medium salt buffer (20 mM Tris-Cl, pH 7.6, 0.1 M NaCl, 1 mM EDTA, 0.1 % SDS), followed by elution of the poly(A)+ RNA with 3 vols of elution buffer (10 mM Tris-Cl, pH 7.6, 1 mM EDTA, 0.05% SDS) preheated to + 65 °C, by collecting 500 μl fractions. The OD260 was read for each collected fraction, and the mRNA containing fractions were pooled and ethanol precipitated at -20°C for 12 h. The poly(A)+ RNA was collected by centrifugation, resu- spended in DEPC-DIW and stored in 5-10 μg aliquots at -80 °C cDNA synthesis First strand synthesis Double-stranded cDNA was synthesized from 5 μg of poly(A)+ RNA by the RNase H method (Gubler et al. (1983) Gene 25, 263- 269; Sambrook et al.(1989), Molecular Cloning: A Laboratory Manual, 2 Ed., Cold Spring Harbor Laboratory, Cold Spring Har¬ bor, New York) using the hair-pin modification. The poly(A)+RNA (5 μg in 5 μl of DEPC-treated water) was heated at 70°C for 8 min. in a pre-siliconized, RNase-free Eppendorph tube, quenched on ice, and combined in a final volume of 50 μl with reverse transcriptase buffer (50 mM Tris-Cl, pH 8.3, 75 mM KC1, 3 mM MgC12, 10 mM DTT, Bethesda Research Laboratories) containing 1 mM of dATP, dGTP and dTTP, and 0.5 mM of 5-methyl-dCTP (Pharmacia) , 40 units of human placental ribonuclease inhibitor (RNasin, Promega), 1.45 μg of oligo(dT)18- Not I primer (Phar¬ macia) and 1000 units of Superscript II RNase H- reverse transcriptase (Bethesda Research Laboratories) . First-strand cDNA was synthesized by incubating the reaction mixture at 45 °C for 1 h. After synthesis, the mRNA:cDNA hybrid mixture was gel filtrated through a MicroSpin S-400 HR (Pharmacia) spin column according to the manufacturer's instructions. Second strand synthesis After the gel filtration, the hybrids were diluted in 250 μl of second strand buffer (20 mM Tris-Cl, pH 7.4, 90 mM KC1, 4.6 mM MgCl2, 10 mM (NH4)2S04, 0.16 mM BNAD+) containing 200 μM of each dNTP, 60 units of E. coli DNA polymerase I (Pharmacia) , 5.25 units of RNase H (Promega) and 15 units of E. coli DNA li- gase (Boehringer Mannheim) . Second strand cDNA synthesis was performed by incubating the reaction tube at 16°C for 2 h, and an additional 15 min at 25°C The reaction was stopped by addi¬ tion of EDTA to 20 mM final concentration followed by phenol and chloroform extractions. Mung bean nuclease treatment The double-stranded (ds) cDNA was ethanol precipitated at - 20°C for 12 hours by addition of 2 vols of 96% EtOH, 0.2 vol 10 M NH4Ac, recovered by centrifugation, washed in 70% EtOH, dried (SpeedVac) , and resuspended in 30 μl of Mung bean nuclease buffer (30 mM NaAc, pH 4.6, 300 mM NaCl, 1 mM ZnS04, 0.35 mM DTT, 2 % glycerol) containing 25 units of Mung bean nuclease (Pharmacia) . The single-stranded hair-pin DNA was clipped by incubating the reaction at 30°C for 30 min, followed by addi¬ tion of 70 μl 10 mM Tris-Cl, pH 7.5, 1 mM EDTA, phenol extraction, and ethanol precipitation with 2 vols of 96% EtOH and 0.1 vol 3M NaAc, pH 5.2 on ice for 30 min. Blunt-ending with T4 DNA polymerase The ds cDNAs were recovered by centrifugation (20 000 rpm, 30 min.), and blunt-ended with T4 DNA polymerase in 30 μl of T4 DNA polymerase buffer (20 mM Tris-acetate, pH 7.9, 10 mM MgAc, 50 mM KAc, l mM DTT) containing 0.5 mM each dNTP and 5 units of T4 DNA polymerase (New England Biolabs) by incubating the re¬ action mixture at +16°C for 1 hour. The reaction was stopped by addition of EDTA to 20 mM final concentration, followed by phenol and chloroform extractions and ethanol precipitation for 12 h at -20°C by adding 2 vols of 96% EtOH and 0.1 vol of 3M NaAc, pH 5.2. Adaptor ligation. Not I digestion and size selection After the fill-in reaction the cDNAs were recovered by centrifugation as above, washed in 70% EtOH, and the DNA pellet was dried in SpeedVac. The cDNA pellet was resuspended in 25 μl of ligation buffer (30 mM Tris-Cl, pH 7.8, 10 mM MgCl2, 10 mM DTT, 0.5 mM ATP) containing 2.5 μg non-palindromic BstXI adap¬ tors (1 μg/μl, Invitrogen) and 30 units of T4 ligase (Promega) by incubating the reaction mix at +16°C for 12 h. The reaction was stopped by heating at + 65°C for 20 min, and then on ice for 5 min. The adapted cDNA was digested with Not I restriction enzyme by addition of 20 μl autoclaved water, 5 μl of 10 x Not I restriction enzyme buffer (New England Biolabs) and 50 units of Not I (New England Biolabs), followed by incubation for 2.5 hours at +37°C The reaction was stopped by heating the sample at +65°C for 10 min. The cDNAs were size-fractionated by agarose gel electrophoresis on a 0.8% SeaPlaque GTG low melting temperature agarose gel (FMC) in 1 x TBE (in autoclaved water) to separate unligated adaptors and small cDNAs. The gel was run for 12 hours at 15 V, the cDNA was size-selected with a cut-off at 0.7 kb by cutting out the lower part of the agarose gel, and the cDNA was concentrated by running the gel backwards until it appeared as a compressed band on the gel. The cDNA (in agarose) was cut out from the gel, and the agarose was melted at 65°C in a 2 ml Biopure Eppendorph tube (Eppendorph) . The sample was treated with agarase by adding 0.1 vol of 10 x agarase buffer (New England Biolabs) and 2 units per 100 μl molten agarose to the sample, followed by incubation at 45°C for 1.5 h. The cDNA sample was phenol and chloroform extracted, and precipitated by addition of 2 vols of 96 % EtOH and 0.1 vol of 3M NaAc, pH 5.2 at - 20°C for 12 h. EXAMPLES Example l Providing novel DNA sequences encoding polypeptide with xylanase activity Novel sequences with xylanase activity were provided ac- cording to the method of the invention using the glycosyl hydrolase family 11 xylanase derived from Bacillus sp. (SEQ ID No 1) as the known structural gene sequence. Identification of conserved regions by alignment An amino acid sequence alignment of ten family 11 xylanases revealed at least 3 conserved sequences. Two of these conserved sequences are used to design appropriate PCR primers for amplification of unknown DNA sequences. The first conserved sequence shown in SEQ ID No. 3 i.e. "DGGTYDIY" corresponding to position 433-456 in SEQ ID NO 1. The second conserved sequence shown in SEQ 4, i.e. "EGYQSSG" corresponding to position 631-651 in SEQ ID NO 1. PCR amplification of the known and unknown partial structural gene sequences Initially the N-terminal end (i.e. Part A) and the C- terminal (i.e. Part C) of the known xylanase gene, in which the unknown sequence (i.e. Part B) is to be inserted, were amplified by PCR (see figure 4) Part A was PCR amplified using the two primers (i.e. primer e and primer a rc ) and as DNA template a plasmid carrying the known xylanase gene (i.e. SEQ ID NO 1). Primer e (shown in SEQ ID NO 5 and figure 1) is an exact N- terminal primer extended with a sequence which included an EcoRI restriction recognition site. Primer a rc (shown in SEQ ID NO 6 and figure 1) is a reverse and complement seguence primer of position 411-432 in SEQ ID NO 1. Part C was PCR amplified using the two primers (i.e. primer f and primer d rc ) mentioned below and as DNA template a plasmid carrying the known xylanase gene. Primer f is an exact reverse and complement C-terminal pri- mer extended with a sequence which having a Sail restriction recognition site is shown in SEQ ID No. 7. Primer d rc (SEQ ID NO 8) was designed on the basis of posi¬ tion 651-672 in SEQ ID No. 1. Part B was PCR amplified using two primers (i.e. primer ab and primer cd) and as DNA template DNA purified from a soil sample using the FastDNA® SPIN Kit. Primer ab (SEQ ID NO 9) has the exact sequence of position 411-432 in SEQ ID 1 extended with degenerated xylanase consensus sequence covering position 433-452 in SEQ ID NO 1 Primer cd (SEQ ID NO: 10) has the exact reverse and complement sequence of position 672-651 in SEQ ID NO 1 extended with degenerated xylanase consensus sequence covering position 650-631 in SEQ ID NO 1. The N-terminal part of the known xylanase gene (Part A) was PCR amplified for 9 min. at 94°C followed by 30 cycles (45 second at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and finally for 7 min. at 72°C This gave a PCR product of approx. 450 bp. The C-terminal part (Part C) of the known xylanase gene was PCR amplified for 9 min. at 94°C followed by 30 cycles (45 se¬ conds at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and fi¬ nally for 7 min. at 72°C This gave a PCR product of approx. 100 bp. The unknown sequences (Part B) was PCR amplified for 9 min. at 94°C followed by 40 cycles(45 seconds at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and finally for 7 min. at 72°C This gave a PCR product of approx. 260 bp. The PCR products mentioned above were carefully purify to avoid remains of template DNA which can produce false positive bands in the following SOE-PCR where the products are joined together to form hybrid sequences. Construction of hybrid sequences Hybrid sequences containing the N- and C-terminal parts of the known xylanase gene with core part of unknown genes was constructed by splicing by overlap extension PCR (SOE-PCR) . Equal molar amounts of Part A, Part B and Part C PCR pro- ducts were mixed and PCR amplified under standard conditions except that the reaction was started without any primers. The reaction started with 9 min. at 94°C followed by 4 cycles (45 seconds at 94°C, 45 seconds at 50°C, 1 min. at 72°C), then primers e and f (SEQ ID No. 5 and 7, respectively) were added, followed by 25 cycles (45 seconds at 94°C, 45 seconds at 50°C, 1 min. at 72°C) and finally 7 min. at 72°C This gave a SOE-PCR product of the expected size of approx. 770 bp. Cloning of the hybrids The SOE-PCR product was purified using the QIAquick PCR Purification Kit Protocol and digested overnight with EcoRI and Sail according to the manufacturers recommendation. The digested product was then ligated into an E . coli expression vector overnight at 16°C (in this case a vector where the hybrid gene is under control of a temperature sensitive lamda repressor promoter) . The ligation mixture was transformed into electromax DH10B E. coli cells (GIBCO BRL) and plated on LB-ampicillin plates containing 0.1% AZCL Birch xylan. After induction of the pro¬ moter (by increasing the temperature to 42°C) xylanase positive colonies were identified as colonies surrounded by a blue halo. Plasmid DNA was isolated from positive E. coli colonies using standard procedures and sequenced with the Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) using an Applied Biosystems 373A automated sequencer according to the manufac- turers instructions. The sequence of a positive clone is shown in SEQ ID NO 11 and the corresponding protein sequence is shown in SEQ ID NO 12. An alignment of the known xylanase sequence (SEQ ID NO 2) and the novel DNA sequence provided according to the method of the invention can be seen in Figure 3. As can be seen the two protein sequences differs between the two identified conserved regions (i.e. SEQ ID NO 3 and SEQ ID NO 4, respectively). Example 2 Efficiency of the method of the invention Degenerated primers were designed on the basis of conserved regions identified by alignment of a number of family 5 cellu¬ lases and family 10 and 11 xylanases found on the Internet in ExPASy under Prosite (Dictionary of protein sites and patterns) . PCR amplification of a number of unknown structural gene sequences from soil and cow rumen samples were performed with various degenerated primers covering identified conserved re- gion sequences to show how effective the method of the inven¬ tion is. The PCR products were cloned into the vector pCR tπ, II, pro¬ vided with the original TA cloning kit from Invitrogen. Said vector provides the possibility to make blue-white screening, the white colonies were selected and the inserts were sequen¬ ced. When editing the Sequence Listing below all sequences out¬ side the two EcoRI sites in the polylinker were removed. Therefore all sequences have a small additional part of the polylinker (i.e. from the EcoRI site to the TT overhang) in both ends of the sequences. These extensions are "GAATTCGGCT" and "AAGCCG". 1. PCR primers were designed on the basis of identified conserved regions #1 GWNLGN and #2 (E/D)HLIFE of cellulases from the glycosyl hydrolase family 5 aiming to provide novel sequences with cellulase activity. SEQ ID NO 13 and 14 show the sequences obtained from a soil sample. SEQ ID NO 15 and 16 show the sequences obtained from a cow rumen sample. 2. PCR primers were designed on the basis of identified conserved regions #1 GWNLGN and #3 RA(S/T)GGNN of cellulases from the glycosyl hydrolase family 5 aiming to provide novel sequences with cellulase activity. SEQ ID NO 17 to 19 show the sequences obtained from a cow rumen sample. 3. PCR primers were designed on the basis of identified conserved regions #2 (E/D)HLIFE and #3 RA(S/T)GGNN of cellula- ses from the glycosyl hydrolase family 5 aiming to provide no¬ vel sequences with cellulase activity. SEQ ID NO 20 to 22 show the sequences obtained from a cow rumen sample. 4. PCR primers were designed on the basis of identified conserved regions #4 HTLVWH and #5 WDWNE of xylanases from the glycosyl hydrolase family 10 aiming to provide novel sequences with xylanase activity. SEQ ID NO 23 to 28 show the sequences obtained from a cow rumen sample. 5. PCR primers were designed on the basis of the identified conserved regions #4 HTLVWH and #6 (F/Y) (I/Y)NDYN of xylanases from the glycosyl hydrolase family 10 aiming to provide novel sequences with xylanase activity. SEQ ID NO 29 to 33 show the sequences obtained from a cow rumen sample. 6. PCR primers were designed on the basis of the identified conserved regions #5 WDWNE and #6 (F/Y) (I/Y)NDYN of xylanases from the glycosyl hydrolase family 10 aiming to provide novel sequences with xylanase activity. SEQ ID NO 34 to 36 show the sequences obtained from a soil sample. SEQ ID NO 37 to 45 show the sequences obtained from a cow rumen sample 7. PCR primers were designed on the basis of the identified conserved regions #8 DGGTYDIY and #9 EGYQSSG of xylanases from the glycosyl hydrolase family 11 aiming to provide novel sequences with xylanase activity. SEQ ID NO 46 to 49 show the sequences obtained from a soil sample. SEQ ID NO 50 to 54 show the sequences obtained from a cow rumen sample. 60 clones with inserts were sequenced and resulted in 43 different sequences all encoding either a part of a cellulase or a part of a xylanase. Only 2 of the 43 sequences were similar to sequence found in the sequence databases Genbank. SEQ ID NO 49 was found to be similar to Xylanase A from Bacillus pumilus . SEQ ID NO 42 was found to be similar to a xylanase from Prevotella ruminicola . Example 3 Construction of novel hybrid DNA sequences encoding polypeptides with endoglucanase activity Novel hybrid DNA sequences with endoglucanase activity were provided by first identifying two conserved regions common for the following family 45 cellulases (see WO 96/29397) : Humicola insolens EGV (disclosed in WO 91/17243) , Fusarium oxysporum EGV (Sheppard et al., Gene (1994), Vol. 15, pp.163-167), Thielavia terreεtriε, Myceliophthora thermophila , and Acremonium sp (disclosed in WO 96/29397). The amino acid sequence alignment revealed two conserved region. The first conserved region "Thr Arg Tyr Trp Asp Cys Cys Lys Pro/Thr" shown in SEQ ID NO 57 corresponds to position 6 to 14 of SEQ ID NO 55 showing the Humicola insolens EG V 43 KDa endoglucanase. The second conserved region "Trp Arg Phe/Tyr Asp Trp Phe" shown in SEQ ID NO 58 corresponding to positions 169 to 198 of SEQ ID NO 55 showing the Humicola insolens EGV 43 KDa endoglucanase. Two degenerate, deoxyinosine-containing oligonucleotide primers (sense; primer s and antisense; primer as) were con¬ structed) for PCR amplification of unknown gene sequences. The deoxyinosines are depicted by an I in the primer sequences. Primers s and primer as are shown in SEQ ID No. 59 and 60 respectively. The Humicola insolenε EG V structural gene sequence (SEQ ID NO 55) was used as the known DNA sequence. A number of fungal DNA sequences mentioned below were used as the unknown sequences. PCR cloning of the family 45 cellulase core region and the linker/CBD of Humicola insolens EG V. Approximately 10 to 20 ng of double-stranded, cellulase-in- duced cDNA from Humicola nigrescens, Cylindrocarpon sp., Fusa- rium anguioides , Gliocladium catenulatum, and Trichothecium ro- seum prepared, as described above in the Material and Methods section were, PCR amplified in Expand buffer (Boehringer Mann- heim, Germany) containing 200 μM each dNTP and 200 pmol of each degenerate Primer s (SEQ ID NO 59) and Primer as (SEQ ID NO 60) a DNA thermal cycler (Perkin-Elmer, Cetus, USA) and 2.6 units of Expand High Fidelity polymerase (Boehringer Mannheim, Germa¬ ny) . 30 cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 min, annealing at 55°C for 2 min, and extension at 72°C for 3 min, followed by extension at 72°C for 5 min. The PCR fragment coding for the linker/CBD of H. insolens EGV was generated in Expand buffer (Boehringer Mannheim, Ger- many) containing 200 μM each dNTP using 100 ng of the pCaHj418 template, 200 pmol forward primer 1 (SEQ ID NO 61) , 200 pmol reverse primer 1 (SEQ ID NO 62) . 30 cycles of PCR were performed as above. Construction of hybrid genes using splicing bv overlap extension (SOE) The PCR products were electrophoresed in 0.7 % agarose gels (SeaKem, FMC) , the fragments of interest were excised from the gel and recovered by Qiagen gel extraction kit (Qiagen, USA) according to the manufacturer's instructions. The recombinant hybrid genes were generated by combining the overlapping PCR fragments from above (ca. 50 ng of each template) in Expand buffer (Boehringer Mannheim, Germany) containing 200 μM each dNTP in the SOE reaction. Two cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 min, annealing at 50 C for 2 min, and extension at 72°C for 3 min, the reaction was stopped, 250 pmol of each end-primer: forward primer 2 (SEQ ID NO 63) encoding the TAKA-amylase signal se¬ quence from A. oryzae , reverse primer 2 (SEQ ID NO 64) was ad¬ ded to the reaction mixture, and an additional 30 cycles of PCR were performed using a cycle profile of denaturation at 94°C for l min, annealing at 55 °C for 2 min, and extension at 72°C for 3 min. Construction of the expression cassettes and heterologous expression in Aspergillus oryzae The PCR-generated, recombinant fragments were electropho- resed in 0.7 % agarose gels (SeaKem, FMC), the fragments were excised from the gel and recovered by Qiagen gel extraction kit (Qiagen, USA) according to the manufacturer's instructions. The DNA fragments were digested to completion with BamHl and Xbal, and ligated into BamHI/Xbal-cleaved pHD414 vector. Co-transfor- mation of A. oryzae was carried out as described in Christensen et al. (1988), Bio/Technology 6, 1419-1422. The AmdS+ transfor¬ mants were screened for cellulase activity using 0.1 % AZC1-HE- cellulose in a plate assay as described above. The cellulase- producing transformants were purified twice through conidial spores, cultivated in 250 ml shake flasks, and the amount of secreted cellulase was estimated by SDS-PAGE, Western blot analysis and the activity assay as described earlier (Kauppinen et al. (1995), J. Biol. Chem. 270, 27172-27178;; Kofod et al. (1994), J. Biol. Chem. 269, 29182-29189; Christgau et. al,(1994), Biochem. Mol. Biol. Int. 33, 917 - 925). Nucleotide sequence analysis The nucleotide sequences of the novel hybrid gene fusions were determined from both strands by the dideoxy chain- termination method (Sanger et al., (1977), Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467) , using 500 ng template, the Taq deoxy-terminal cycle sequencing kit (Perkin-Elmer, USA) , fluorescent labeled terminators and 5 pmol of synthetic oligonucleotide primers. Analysis of the sequence data was performed according to Devereux et al., 1984 (Devereux et al., (1984), Nucleic Acids Res. 12, 387-395). The provided novel hybrid DNS sequences an the deduced protein sequences are shown in SEQ ID NO 65 to 74. SEQ ID NO 65 shows the hybrid gene construct comprising the family 45 cellulase core region from Humicola nigrescens and the linker/CBD of Humicola insolens EG V. SEQ. ID No 66 shows the deduced amino acid sequence of the hybrid gene construct. SEQ ID NO 67 shows the hybrid gene construct comprising the family 45 cellulase core region from Cylindrocarpon sp. and the linker/CBD of Humicola insolenε EG V. SEQ ID NO 68 shown the deduced amino acid sequence of the hybrid gene construct. SEQ ID NO shows the hybrid gene construct comprising the family 45 cellulase core region from Fuεarium anguioides and the linker/CBD of Humicola insolenε EG V. SEQ ID NO 70 shows the deduced amino acid sequence of the hybrid gene construct. SEQ ID NO 71 shows the hybrid gene construct comprising the family 45 cellulase core region from Gliocladium catenulatum and the linker/CBD of Humicola insolenε EG V. SEQ ID NO 72 shows the deduced amino acid sequence of the hybrid gene construct. SEQ ID NO 73 shows the novel gene construct comprising the family 45 cellulase core region from Trichothecium roseum and the linker/CBD of Humicola insolenε EG V. SEQ ID NO 74 shows the deduced amino acid sequence of the hybrid gene construct. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Novo Nordisk A/S (B) STREET: Novo Alle (C) CITY: Bagsvaerd (E) COUNTRY: Denmark (F) POSTAL CODE (ZIP): DK-2880 (G) TELEPHONE: +45 4444 8888 (H) TELEFAX: +45 4449 3256 (ii) TITLE OF INVENTION: Method for providing novel DNA sequences (iii) NUMBER OF SEQUENCES: 74 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 747 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (B) STRAIN: Bacillus sp. AC13, NCIMB No. 40482 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..747 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATG AGA CAA AAG AAA TTG ACG TTC ATT TTA GCC TTT TTA GTT TGT TTT 48 Met Arg Gin Lys Lys Leu Thr Phe He Leu Ala Phe Leu Val Cys Phe 1 5 10 15 GCA CTA ACC TTA CCT GCA GAA ATA ATT CAG GCA CAA ATC GTC ACC GAC 96 Ala Leu Thr Leu Pro Ala Glu He He Gin Ala Gin He Val Thr Asp 20 25 30 AAT TCC ATT GGC AAC CAC GAT GGC TAT GAT TAT GAA TTT TGG AAA GAT 144 Asn Ser He Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp 35 40 45 AGC GGT GGC TCT GGG ACA ATG ATT CTC AAT CAT GGC GGT ACG TTC AGT 192 Ser Gly Gly Ser Gly Thr Met He Leu Asn His Gly Gly Thr Phe Ser 50 55 60 GCC CAA TGG AAC AAT GTT AAC AAC ATA TTA TTC CGT AAA GGT AAA AAA 240 Ala Gin Trp Asn Asn Val Asn Asn He Leu Phe Ar.g Lys Gly Lys Lys 65 70 75 80 TTC AAT GAA ACA CAA ACA CAC CAA CAA GTT GGT AAC ATG TCC ATA AAC 288 Phe Asn Glu Thr Gin Thr His Gin Gin Val Gly Asn Met Ser He Asn 85 90 95 TAT GGC GCA AAC TTC CAG CCA AAC GGA AAT GCG TAT TTA TGC GTC TAT 336 Tyr Gly Ala Asn Phe Gin Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr 100 105 110 GGT TGG ACT GTT GAC CCT CTT GTC GAA TAT TAT ATT GTC GAT AGT TGG 384 Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr He Val Asp Ser Trp 115 120 125 GGC AAC TGG CGT CCA CCA GGG GCA ACG CCT AAG GGA ACC ATC ACT GTT 432 Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr He Thr Val 130 135 140 GAT GGA GGA ACA TAT GAT ATC TAT GAA ACT CTT AGA GTC AAT CAG CCC 480 Asp Gly Gly Thr Tyr Asp He Tyr Glu Thr Leu Arg Val Asn Gin Pro 145 150 155 160 TCC ATT AAG GGG ATT GCC ACA TTT AAA CAA TAT TGG AGT GTC CGA AGA 528 Ser He Lys Gly He Ala Thr Phe Lys Gin Tyr Trp Ser Val Arg Arg 165 170 175 TCG AAA CGC ACG AGT GGC ACA ATT TCT GTC AGC AAC CAC TTT AGA GCG 576 Ser Lys Arg Thr Ser Gly Thr He Ser Val Ser Asn His Phe Arg Ala 180 185 190 TGG GAA AAC TTA GGG ATG AAC ATG GGG AAA ATG TAT GAA GTC GCG CTT 624 Trp Glu Asn Leu Gly Met Asn Met Gly Lys Met Tyr Glu Val Ala Leu 195 200 205 ACT GTA GAA GGC TAT CAA AGT AGC GGA AGT GCT AAT GTA TAT AGC AAT 672 Thr Val Glu Gly Tyr Gin Ser Ser Gly Ser Ala Asn Val Tyr Ser Asn 210 215 220 ACA CTA AGA ATT AAC GGT AAC CCT CTC TCA ACT ATT AGT AAT GAC AAG 720 Thr Leu Arg He Asn Gly Asn Pro Leu Ser Thr He Ser Asn Asp Lys 225 230 235 240 AGC ATA ACT CTA GAT AAA AAC AAT TAA 747 Ser He Thr Leu Asp Lys Asn Asn * 245 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Arg Gin Lys Lys Leu Thr Phe He Leu Ala Phe Leu Val Cys Phe 1 5 10 15 Ala Leu Thr Leu Pro Ala Glu He He Gin Ala Gin He Val Thr Asp 20 25 30 Asn Ser He Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp 35 40 45 Ser Gly Gly Ser Gly Thr Met He Leu Asn His Gly Gly Thr Phe Ser 50 55 60 Ala Gin Trp Asn Asn Val Asn Asn He Leu Phe Arg Lys Gly Lys Lys 65 70 75 80 Phe Asn Glu Thr Gin Thr His Gin Gin Val Gly Asn Met Ser He Asn 85 90 95 Tyr Gly Ala Asn Phe Gin Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr 100 105 110 Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr He Val Asp Ser Trp 115 120 125 Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr He Thr Val 130 135 140 Asp Gly Gly Thr Tyr Asp He Tyr Glu Thr Leu Arg Val Asn Gin Pro 145 150 155 160 Ser He Lys Gly He Ala Thr Phe Lys Gin Tyr Trp Ser Val Arg Arg 165 170 175 Ser Lys Arg Thr Ser Gly Thr He Ser Val Ser Asn His Phe Arg Ala 180 185 190 Trp Glu Asn Leu Gly Met Asn Met Gly Lys Met Tyr Glu Val Ala Leu 195 200 205 Thr Val Glu Gly Tyr Gin Ser Ser Gly Ser Ala Asn Val Tyr Ser Asn 210 215 220 Thr Leu Arg He Asn Gly Asn Pro Leu Ser Thr He Ser Asn Asp Lys 225 230 235 240 Ser He Thr Leu Asp Lys Asn Asn 245 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Conserved region" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Asp Gly Gly Thr Tyr Asp He Tyr 1 5 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Conserved region" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Glu Gly Tyr Gin Ser Ser Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer e" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GCGAATTCAT GAGACAAAAG AAATTGACG 29 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer a rc " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: AACAGTGATG GTTCCCTTAG GC 22 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer f " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CTAGAGTCGA CTTAATTGTT TTTATCTAGA G 31 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer d rc " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: AACAGTGATG GTTCCCTTAG GC 22 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer ab " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GCCTAAGGGA ACCATCACTG TTGAYGGXGG XACXTAYGAY AT 42 (Y=C or T, X= 25% A and 75% Inosin) (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer cd " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: AATGCTATAT ACATTAGCAC TTCCXSWXSW YTGGTAXCCY TC 42 (S=G or C, W=A or T, Y=C or T, X= 25% A and 75% Inosin) (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 747 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: hybrid DNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..747 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATG AGA CAA AAG AAA TTG ACG TTC ATT TTA GCC TTT TTA GTT TGT TTT 48 Met Arg Gin Lys Lys Leu Thr Phe He Leu Ala Phe Leu Val Cys Phe 1 5 10 15 GCA CTA ACC TTA CCT GCA GAA ATA ATT CAG GCA CAA ATC GTC ACC GAC 96 Ala Leu Thr Leu Pro Ala Glu He He Gin Ala Gin He Val Thr Asp 20 25 30 AAT TCC ATT GGC AAC CAC GAT GGC TAT GAT TAT GAA TTT TGG AAA GAT 144 Asn Ser He Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp 35 40 45 AGC GGT GGC TCT GGG ACA ATG ATT CTC AAT CAT GGC GGT ACG TTC AGT 192 Ser Gly Gly Ser Gly Thr Met He Leu Asn His Gly Gly Thr Phe Ser 50 55 60 GCC CAA TGG AAC AAT GTT AAC AAC ATA TTA TTC CGT AAA GGT AAA AAA 240 Ala Gin Trp Asn Asn Val Asn Asn He Leu Phe Arg Lys Gly Lys Lys 65 70 75 80 TTC AAT GAA ACA CAA ACA CAC CAA CAA GTT GGT AAC ATG TCC ATA AAC 288 Phe Asn Glu Thr Gin Thr His Gin Gin Val Gly Asn Met Ser He Asn 85 90 95 TAT GGC GCA AAC TTC CAG CCA AAC GGA AAT GCG TAT TTA TGC GTC TAT 336 Tyr Gly Ala Asn Phe Gin Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr 100 105 110 GGT TGG ACT GTT GAC CCT CTT GTC GAA TAT TAT ATT GTC GAT AGT TGG 384 Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr He Val Asp Ser Trp 115 120 125 GGC AAC TGG CGT CCA CCA GGG GCA ACG CCT AAG GGA ACC ATC ACT GTT 432 Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr He Thr Val 130 135 140 GAC GGG GGG ACG TAT GAT ATC TAC AAG CAC CAA CAG GTC AAT CAG CCA 480 Asp Gly Gly Thr Tyr Asp He Tyr Lys His Gin Gin Val Asn Gin Pro 145 150 155 160 TCT ATT CAG GGC ACC GCC ACC TTC AAT CAG TAC TGG TCG ATT CGA CAG 528 Ser He Gin Gly Thr Ala Thr Phe Asn Gin Tyr Trp Ser He Arg Gin 165 170 175 AGC AAG CGG ACC AGC GGC ACT GTC ACT ACG GCA AAC CAC TTT AAT GCC 576 Ser Lys Arg Thr Ser Gly Thr Val Thr Thr Ala Asn His Phe Asn Ala 180 185 190 TGG GCT GCT CTT GGC ATG AAT ATG GGT GCA TTC AAT TAC CAG ATC CTC 624 Trp Ala Ala Leu Gly Met Asn Met Gly Ala Phe Asn Tyr Gin He Leu 195 200 205 GTT ACT GAG GGC TAC CAA TCT ACC GGA AGT GCT AAT GTA TAT AGC AAT 672 Val Thr Glu Gly Tyr Gin Ser Thr Gly Ser Ala Asn Val Tyr Ser Asn 210 215 220 ACA CTA AGA ATT AAC GGT AAC CCT CTC TCA ACT ATT AGT AAT GAC AAG 720 Thr Leu Arg He Asn Gly Asn Pro Leu Ser Thr He Ser Asn Asp Lys 225 230 235 240 AGC ATA ACT CTA GAT AAA AAC AAT TAA 747 Ser He Thr Leu Asp Lys Asn Asn * 245 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Arg Gin Lys Lys Leu Thr Phe He Leu Ala Phe Leu Val Cys Phe 1 5 10 15 Ala Leu Thr Leu Pro Ala Glu He He Gin Ala Gin He Val Thr Asp 20 25 30 Aβn Ser He Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp 35 40 45 Ser Gly Gly Ser Gly Thr Met He Leu Asn His Gly Gly Thr Phe Ser 50 55 60 Ala Gin Trp Asn Asn Val Asn Asn He Leu Phe Arg Lys Gly Lys Lys 65 70 75 80 Phe Asn Glu Thr Gin Thr His Gin Gin Val Gly Asn Met Ser He Asn 85 90 95 Tyr Gly Ala Asn Phe Gin Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr 100 105 110 Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr He Val Asp Ser Trp 115 120 125 Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr He Thr Val 130 135 140 Asp Gly Gly Thr Tyr Asp He Tyr Lys His Gin Gin Val Asn Gin Pro 145 150 155 160 Ser He Gin Gly Thr Ala Thr Phe Asn Gin Tyr Trp Ser He Arg Gin 165 170 175 Ser Lys Arg Thr Ser Gly Thr Val Thr Thr Ala Asn His Phe Asn Ala 180 185 190 Trp Ala Ala Leu Gly Met Asn Met Gly Ala Phe Asn Tyr Gin He Leu 195 200 205 Val Thr Glu Gly Tyr Gin Ser Thr Gly Ser Ala Asn Val Tyr Ser Asn 210 215 220 Thr Leu Arg He Asn Gly Asn Pro Leu Ser Thr He Ser Asn Asp Lys 225 230 235 240 Ser He Thr Leu Asp Lys Asn Asn * 245 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 409 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS1/9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GAATTCGGCT TGGGTGGAAT CTGGGGAACA CGTTGGATGC TACCGGAGAC TGGATCAAAG 60 GGCCGTCCGT GAGCGCCTAC GAGACCGCCT GGGGCAATCC CGTCACCACC AAGGCTATGT 120 TCGACGGCAT CAAAGCGTCC GGCTTCAACT TTGTTCGCAT TCCCGTGGCG TGGTCCAACA 180 TGATGGGCCC GGACTATACC ATTAACCCGG CGTTGATGGC GAGAGTCGAG AAGTGGTGAA 240 TTACGGTCTG GCCGACAACA TGTATGTCAT GATCAACATC CACTGGGACG CGGCTGGATC 300 ACTAAATTCC CACCAACTAC GACGAAAGCA TGAAGAAGTA TAAGGCGGTC TGGAGCCAGA 360 TCGCCGACCA TTTCAAAGCT ACTCCGACCA CCTCATCTTC GAAAAGCCG 409 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 408 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS1/12 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: AATTCGGCTT GGGTGGAATC TGGGGAACAC TCTGGAAGCC TGCGGCGGGA TCAAATGCAG 60 TTCCGTGCGC GATTTCGAGA CGGCTTGGGG CAACCCCGTC ACGACCAAGG CCATGATCGA 120 CGGCGTCAAG GCGGCCGGCT TCAGGTCCAT ACGCATCCCC GTCGCCTGGT CGAACCTGAT 180 GGGACCTAAG CCCGACTACA CTATCAATAA GAAGCTGATG GCACGAGTCG AGCAGGTCGC 240 CCGGTACGGC CTCGACAACG ACATGTACGT CATCATCAAC ATTCACTGGG ACGCGGCTGG 300 ATCCACCGCT TCTCCACCGA CTACAACGAA ATGCATGARG AATTACAAGG CGGTGTGGGG 360 CCAGGTAGCC GACCATTTCA AGGGCTACTC CGACCACCTC ATCTTCGA 408 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 416 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KN1/9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: AATTCGGCTT CTCGAAGATG AGGTGGTCGG AGTAGCCTTT GAAATGGTCG GCGATCTGGC 60 TCCAGACCGC CTTATACTTC TTCATGCTTT CGTCGTAGTT GGTGGGGAAT TTAGTGATCC 120 AGCCGCCGTC CCAGTGGATG TTGATCATGA CATACATGTT GTCGGCCAGA CCGTAATTCA 180 CCACTTCCTC GACTCTCGCC ATCAACGCCG GGTTAATGGT ATAGTCCGGG CCCATCATGT 240 TGGACCACGC CACGGGAATG CGAACAAAGT TGAAGCCGGA CGCTTTGATG CCGTCGAACA 300 TAGCCTTGGT GGTGACGGGA TTGCCCCAGG CGGTCTCGTA GGCGCTCACG GACGGCCCTT 360 GATCCAGTC TCCGGTAGCA TCCAACGTGT TCCCCARATT CCACCCAAGC CGAATT 416 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM1/2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: AATTCGGCTT GTTCCGCAAG CGTCAAAGGG GATGTGATGT ACCAGATCAA GGCAAAGCTC 60 GGTCTGAAAT AAAACTAGTC AAAACTAGCC AAAACTAGTC AGGCTAGTCA GAACCAGTTA 120 GCACAATCGT AAAAACTAAA AGTATGAGCG ACGGCAATTT CAACCGCGCC CTCCTGCCGA 180 AGAACGAACT CTCTGCAGGA CTCAGGGCTG GCAAAGCACA GATGCGCACC AAGGCTGAAA 240 CAGGCGTTGG AGACTGTACT CGACNAATAC TTCCCCTCTG CCGACATGTC GCTCCGAAAC 300 GCAATCCACG AACGATCCTC CAACTCTTAC AACAGTAGGA CAAAGGTGAA ACGTATTTAA 360 TTATGCTTCC TGAATTNTCA TTAACACNAT GCCTGTGTGG CACCCATCCG CGTNTTCAAT 420 GGTGTTCACC AGGGCATCCT TTACTCATCC CACAGGTTAA GCAANTGGCC AAANAACACC 480 GTCCGGCTTC 490 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 492 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KN2/2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: AATTCGGCTT GTTGTTGCCG CCGGTGGTGC GGACCACGTC AATAAAAGTC TGGTTGTAAG 60 AATTCTGCAC AGCCAGATTC TCAGGCTCGG GCTTGCCCCA GTTATCGCGC AGGTGAACCT 120 CGTTAGTACC AGCAAAGGCT ACGCGGTAGT CGTAGTTGGC AAACTCGCTG GCGATATTCA 180 GCCACAGCAG GGCGAGTTTC TGGTTGTTCT CGTCCTTGTA CTGATAGGTA GGACRACCCT 240 CCAGCCACTT GTCGTGATGC GTATTGATGA TGACTTTTAG GTCATTCTCG AAGCACCARC 300 CCACAACCTC TTTGATACGT GCCAGCCAAG CCTTGTCAAT GCTCATGGCA ACGGGATTGG 360 TGATGTTGCA CTGCCACCGG AMSGGAATGC GGATGGCGTT RAAAC:TGCA TCCTTGACTG 420 CCTTGATAAC TTTTTTGTTA CAACGGGATT GCCCCATGCC GTCTCACCCT TAATACTGTT 480 CTCATACATC CG 492 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 574 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM2/5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: AATTCGGCTT GTTGTTGCCG CCGGTGGTAC GGATGGTGTT CACCACCAAC TGGTTCCACT 60 CGTTGAGGGT TTTATACTGC TTACCGCCAT CGGTACGGTT TGCGCCCCAT CCCCAGCCGC 120 CGTCCTGAAT CTCGTTGAAC GACTCGAATA TGAGGAATTC GCCCTTGTCC TTGAAGGCTT 180 CGGCAATCTG TTTCCANGTT TTCTCAATAC GGTTCTTGAT GTTGCTGTTG GTCGTTGAAT 240 TGTTGGCAGC GCCCTTAATG TCAACCAGTA CTCATCGTGA TGCATGTTCA GGATNACNTT 300 CAGTCCGGCA CTTCGGCCCA CTCCACATTC TGCCTGACTT CTGCTATGTA TTTAGCATCT 360 ATCCCCATTC CAAATGTTTC TGGTANTTGC CCATGTTACC CGANACTTAN GTGCTGGCAC 420 AACGTTTTTA NGTTTGTTAA AAACCGCAAA GGCTTGGCAT TTCCAATATC CCANTGGGGA 480 ACCNAACNTC NCACCCNGCC GGTACAAATG GTNCCCCNTT TCCCCCAACC CAAATCCNCC 540 NCNGGGGGCC GTTACNATTG NATCNAACCG GTAC 574 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 520 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM2/6 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: AATTCGGCTT GTTGTTGCCG CCGGTGGTTC TCACGGTGGT GACGAAGCTC TGAGCATANC 60 TGTTGATGGC GTTGTAGGCC GATGTGGCTA TGGCTTCGTT GTACCTGCCG GTAGCGGCAA 120 AGGATGCGAA ACACCAGGAG CTCAAGGGAT CCAGCATCTC GTTGAAGCTC TCGAAGAGCA 180 AGCGCTGTCC GCAGTCCCGG AATTCCTGTG CTATCTGCTG CCACAGACGT TCATANCGGG 240 AGCGGTTCAN CGCGTATTTG TCCTCGGANG CCTTGATCCA CNACTTGAAA CNANTTGCTG 300 TCTGCGCCCG TGTCGTGGTG AACGTTGAAT NATGCAGTAC AAGCCCTGGT CTAGGANACT 360 ATCACCACTT CATGCACGCG GGCCATCCAC GCCNCATCCA CNTTGCCGGC GCTGTCCATN 420 TTGTTATACC ACTTCATGGC CCACGGATGG CACCAAACCC GGATCTTTNT CNTCCTGAAN 480 AACAANGGGT GGTGGGATAT TAACCCAACA GGTCCGAAGA 520 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 194 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM3/2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: AATTCGGCTT GAGCACCTGA TTTTTGAGGG CTACAACGAG ATGCTCGACA AGTATGACTC 60 CTGGTGTTTT GCCACCTTCG GACGCTCGGC AGGCTATAAC GCTACAGACG CCGCCGATGC 120 CTATAAAGCC ATCAACAACT ATGCCCAGAG CTTCGTCAAC GCCGTACGCA CCACCGGCGG 180 CAACAACAAG CCG 194 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 160 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM3/8 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: AATTCGGCTT GAGCACTTGA TTTTCGAGGC CTACAACGAG ATGCTCGATG CCCAGAGCTC 60 GTGGAACTTT GCCCAGACCA GCACAGCCTA TGATGCTATC AACAACTATG CCCAAAGCTT 120 CGTCAACATT GTTCGTACCA GCGGCGGCAA CAACAAGCCG 160 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 193 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM3/9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: AATTCGGCTT GAGCATTTGA TCTTCGAGAG TTACAACGAG ATGCTCGATA CGGAAGATTC 60 CTGGTGCTTC GCCTCGTTTG CAGCGCAGGG CAGTTACAAT GCCACCATCG CGCGTTCGGC 120 CTACAACGGC ATTAATAGCT ATGCGCAGAC TTTCGTCAAC ACCGTACGTA CCACCGGCGG 180 CAACAACAAG CCG 193 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 166 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: AATTCGGCTT CAYACGCTGG TGTGGCACTC TCAGATCGGT CGTTGGATGA CTGCCGAGGG 60 TACAACCAAG GAGCAGTTCT ATGCTCGTAT GAAGAACCAT ATCCAGGCTA TCGTTACTCG 120 TTACAAGGAT GTGGTGTACT GCTGGGACGT CGTCAACGAG AAGCCG 166 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: AATTCGGCTT CTCGTTAACG ACGTCCCAGG CATCGATCTT ACCGCAGAAA TGGCCGGCTA 60 CCGTCTCTAT GTAACTGCGC ATGGTCTCAA CCATCTCATC GTGGCTCTTG GGAGTGCCGT 120 CAGCGTGGTT GAAAAAGAAA TCGGGAGTCT GATTGTGCCA CACCAGCGTA TGAAGCCG 178 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 181 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: AATTCGGCTT CAYACGCTGG TGTGGCACTC GCAGGCACCC GACTGGTGGT TTACCAACGG 60 CTATGCTGCC AGCCCTGTCT CAAAGGAAGT GCTGAAAGAG CGGCTCATCA AGCATATTAA 120 GACCGTTGTT GGCCATTTCA AGGGCCAAGT CTTTGGCTGG GACGTCGTCA ACGARAAGCC 180 G 181 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 199 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/7 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: AATTCGGCTT CATACGTTGG TGTGGCACAA TCAGACGCCG GCCTGGTTCT TCCGCAGGGG 60 CTACAACGAG AACCTGCCTC TGGCGGACCG CGAGACCATG CTGGCGAGGC TGGAGAGCTA 120 TATCCGCGGT GTGCTGACCT ATGTGCAGGA GAATTATCCC GGGATCGTCT ACGCCTGGGA 180 CGTCGTCAAC GAGAAGCCG 199 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 185 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/8 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: AATTCGGCTT GGCACGGACA GACGCCGCAG TGGTTCTTCT ACGAGAACTA TAATACTTCA 60 GGAAAACTTG CAAGCAGGGA AACGATGCTG GCAAGAATGG GAAACTATAT TAANGGCGTG 120 CTTGGCTTCG TGCAGGACAA TTATCCCGGC GTCATCTATG CGTGGGACGT TGTCAACGAG 180 AACCG 185 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 208 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM4/9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: ATCTGCAGAA ATTCGGCTTC TCGTTAACGA CGTCCCATGC ATAGATGACA CCCGGATATT 60 CACTCTGGAT AAAACCAAGC ACACCCTTTA TATAATTTTC AAGTCTGGCA AGCATGGTCT 120 CTCTGTCGGT ATAGGGAAAT GACTCGTTAT AGTGCTCACA GAAAAACCAC TTCGGTGTCT 180 GATTGTGCCA CACCAGCGTA TGAAGCCG 208 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 310 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM5/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: AATTCGGCTT GTTGTAGTCG TTGTAGTACA GCTTGCAGTT TGAAGGAGCG TACTTTCTTG 60 CATATGTGAA CGCTTTCTCA ATAAATGCGT TGCTGCCGTA AACCTGTACC CAAGGGANAA 120 GCGCCGTTGC CGTACCCGGA ACTCTTGCTC CGCCGTTGTT ACGTGTTCTG TTGGAGTCAC 180 ANAAAATACA CTCGTTGCAG ACATCTAAAG CTTAAAGGTT AATCCGGGAT ACTGTGACTG 240 ATAGGCCGAA CATATCTTGA AGTTACCTTC CAGTCCNGGT CCATACGGAA TGCTACCAGC 300 TTCGCCGTCC 310 (2) INFORMATION FOR SEQ ID NO: 30: U) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM5/2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: AATTCGGCTT GTTGTANTNG TTGWWGAAGA NGTGGCAGNT TGCCGGTGCC GCATCATGGG 60 CATATTCAAA TGCCTTTGCA ATGAAGCTGT TGTCACCGTA AACCTGCACC CACGGGGACT 120 TGCCGTCATT GTAACCCGGC TCACGGGCGC CGCCTGCACC ACGCGTACGC GCATCGCTGT 180 CGGAGATACA CTCGTTGCAG ACGTCGTARG CGTANARGTT CAGCGTCNGA TAGTTGTTCT 240 TGTACATTGC AAMCATATTG TCAATGTANC YCTTGANGCG CTGGTTCATG ACAGTGGANT 300 TCACCCACTG ACCGCCGTCC TGGAAAGTTA TCCTTGAAAN AACCAGANCG GARTCTGGRA 360 GTGCCACNCC ANCGTRTGAA GCCG 384 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM5/4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: AATTCGGCTT CATACGTTGG TGTGGCACAA TCAGACGCCC GTATGGTTTT TTAAGGAAAA 60 CTGGGAAAAT GACTGGAACG CGCCTGCCGC CCCCAAAGAA ATCCTGCTCG CCCGCCTGGA 120 AAACTATATC CGGGATGTCA TGCGGCATGT GAATACCTGT TTCCCCGGTG TGGTCTACAC 180 CTGGGATGTG GTGAACGAAG CCATCGAACC GGGGCAGGGC GGTCCCGGCC TGTTCCGGAA 240 CCGCAATCCC TGGTTTGCTT TCACAGGCCA NGATTTCCTG CCGGCTGCCT TCCGGGCCCC 300 CGCGAAAACN AAGTCCCGGG ACAGAACCTG TGCTACAACG ACTACAACAA GCCG 354 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 base pairβ (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM5/5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: AATTCGGCTT CATACGCTGG TGTGGCACAG CCAGACTCCT GACTGGTTCT TCAAGGAGAA 60 CTTCAGCTCA AACGGTCAGC TCGTATCAAA GGATATAATG AATCAGCGTA TCGAAAACTA 120 CATCAAGAAC GTATTCACAA TGCTCAATGC AGAGTATCCT ACAGTTCAGT TCTATGCTTA 180 CGATGTAGCT AACGAGTGTA TGGCTGACAG CAGAAACGGC GGTCTCAGAC CGGCTGGCAT 240 GAATCAGCAG AACGGCGAAT CCCCATGGAA TCTTATCTAC GGCGACAACA GCTACCTCGA 300 TGTANCATTC AAGGCTGCTA AGAAATTATG CTCCTGCTGG CTGCNAACTT TTCTTCAACG 360 ACTACAACAA GCCG 374 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM5/6 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: AATTCGGCTT CATACGCTGG TGTGGCACAG CCAGACTCCC GAGTGGTTCT TCAAGGAGGA 60 CTTCGACGAG AAGAAGGATT ACGTTTCTCC CGAAAAGATG AAGAAGCGTA TGGAGAACTA 120 CATCAAGAGC TTCTTCACAA CACTTACAGA GCTCTATCCC GACGTTGACT TCTATGCCTG 180 CGACGTTGTA AACGANGCAT GGACAGACGA CGGAAAGCCC CGTGAGGCAG GTCACTGTTC 240 ACAGTCCAAC AACTACGGCG CTTCCGACTG GGTTGCTGTA TTCGGCGACA ACTCATTCAT 300 CGACTACGCT TTCGAGTATG CAAGAAAGTA TGCTCCCGAN GGCTGCAAGC TCTACTACAA 360 CGACTACAAC AAGCCG 376 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 166 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS6/3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: AATTCGGCTT TGGGATGTGG TGAACGAGGC CTTCAACGAA GACGGTTCAC GGCGCAGCGA 60 CGTTTTCCAG AATGTGCTCG GCAACGGCTA TATCGAGCAG GCATTCAGGA CCGCGCGTGC 120 GGCTGACCCC AATGCCAAAC TGTGCTACAA CGACTACAAC AAGCCG 166 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 151 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS6/5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AATTCGGCTT GTTGTAGTCG TTGTTGAACA GGCGGGTGGT TGGGTCTACC TCATGAGCAA 60 GTTGATACCA GTGCACAACA GCATCGAGGC CGCCGAGGGC ATCATAAACC TCGTGGTTAT 120 CTACCGGCTC GTTCACCACA TCCCAAAGCC G 151 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 166 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS6/13 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: AATTCGGCTT GTTGTAGTCG TTGTAGCACA GTTTGGCATT GGGATCTGTA ACCCGTGCAG 60 CTTTGAATGC CTCTTCAATA TAGCTATTGC CAATCAGCCG TTGGAAGATT GAGGCACGCC 120 GTGAGCCATT GTCTTCGAAG GCCTCATTCA CCACATCCCA AAGCCG 166 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 250 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS6A/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: AATTCGGCTT GTTGTAGTCG TTGWTGMAGA GTTTTACATC TTTTGGACCA TATTTGCGAG 60 CCAGACGACA GGCCTGACGG ACGTAGTCGA TATCACCCAG ATAGTCCTGC CAGTAGAAAT 120 TATCGCCGCC CACATCCCAT GTGGCATCTG GATTACCATT AGGATTATAC TTAGCAGAGT 180 GTTGTAATAA GTAGTTGCCT TGTCCGTCAT CACCACCACC AGAGATCGCC TCRTTCACCA 240 CATCCCAAAG 250 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6A/4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: AATTCGGCTT TGGGAYGTGG TGAAYGAGGC GATAGAGCTT AACGACAAGA CCGAAACCGG 60 ACTTCGTAAT TCATACTGGT ATCAAATAAT CGGTGACGAT TTCATATATT ACGCATTTCG 120 CTATGCATAT GACGCAAGAG AGGAACTGTG CGTTAAATAT GCGGCCGAGT ACGGCATTGA 180 CCCTTCGGAC AAAGAAGCGC TTAAAGCCAT CCGCCCCGCT TTCTGCAACA ACGACTACAA 240 CAAGCCG 247 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 238 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6A/5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: AATTCGGCTT TGGGATGTGG TGAACGAGGC TATCTCGGGT GGCGACAGTG ACGGCGACGG 60 TTACTACGAC CTCCAGCATT CCGAGGGCTA TAAGAACGGC ACTTGGGATG TAGGCGGCGA 120 TGCCTTCTAC TGGCAGGACT ACATGGGCGA CCTGGATTAC GTRCGTCAGG CTTGCCGACT 180 GGCCCGCAAA TACGGCCCTG AGGATGTGAA GCTYTKCATC AACGACTACA ACAAGCCG 238 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6A/7 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: AATTCGGCTT GTTGTAGTCG TTGATGCACA ACAGGGCATT GGGGTCGGCC TCACGGGCAA 60 ACTCGAAAGC TTTGGCAATG AACTCGTCGC CGCAGAGTTT GTAATGACGA CTCTCACGAT 120 AGGGGCTGGG AGCCTGACCT GGACGGCGTC CGAAACCGCC AAAGCCACCA AAGCCACCAA 180 AGCCGCCACC GTCGGAAATG GCCTCGTTCA CTACATCCCA AAGCCG 226 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 205 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6B/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: ATCTGCAGAA ATTCGGCTTT GGGACGTGGT GAACGAGGCT ATGGCCGACG ACGTTCGCCG 60 CTCGCCCTGG AACCCGAATC CGTCGCCTTA CCGCAACTCG AAACTCTATC AGTTGTGCGG 120 TGATGAGTTC ATCGCTAAAG CATTCCAATT CGCCCGTGAG GCCGACCCGA ACGCACAATT 180 GTGCATCAAC GACTACAACA AGCCG 205 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 235 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6B/2 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: AATTCGGCTT GTTGTAGTCG TTGATGAAGA GCTTCATATC CTGTGGACCA TACTTGCGAG 60 CCAGCTTAAC GGCAGTACGA ACATAGTCGA TATCGCCCAG ATAATCCTGC CAGAAGAAGC 120 TCTCGGTTGC AGCCTTTTCT GGATCTTCCT GATCCTTCAG GTGCTGCAAA GCATATACGC 180 CCTCAGCATC GGCATGTCCG CTTGAGAGTG CCTCGTTCAC CACATCCCAA AGCCG 235 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6B/3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: AATTCGGCTT GTTGTAGTCG TTGATGAANA GTTTCAAGTC TTCCGGGTTG CCCTTGAAGT 60 GCTTGCGCGC ACTCTTAACC GCGGTACGCA CGTATTCGAN GTCGCCCATA TCGTCCTGCC 120 AAAAGAANAG CCATTCTGCA CTGAAGTCGG GTCGGTGTTG CGGCTACTGT TGTGCTGAAN 180 GGGATAATTG CCCTGCCCAT CGTTGCCGCC GCCAGANATA CCTCGTTCAC ACGTCCCAAA 240 GCCG 244 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 212 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6B/4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: AAATTCGGCT TGTTGTAGTC GTTGATGTAC AGGACCGGGG CTTTGCCGTA CTTGGCGCAA 60 GCCTCTGTTG CATAGGCGAA TGCAGCATCA ACCCAGTCTT TGGTGCTCGG GTAATAATTG 120 CCCCAGACAA AGTCGTTGGC AGATGCTCCC TGGGTGCGGA ATGCCCCGCC GGCACCGTCT 180 GCAAAGGTCT CGTTCACCAC GTCCCAAAGC CG 212 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 190 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM6B/5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: AATTCGGCTT GTTGTAGTCG TTGTAGAACA GACCTGCATT AGGATCAGCC TCGTGAGCAA 60 ACTGGAATGC CTTGAGGATG AACTCGTCAC CGCAGAGCTG ATAAGCGGTT GACTGACGGA 120 ATGACTGCTC GTAAGGAACA TCGGGGTTGT TGCCGTCGCT CATTGCCTCG TTTACCACGT 180 CCCAAAGCCG 190 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS8/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: AATTCGGCTT GACGGGGGGA CGTAYGAYAT CTACGAGACC ACCCGCTACA ACGAACCCTC 60 CATCATCGGC ACCGCCACCT TCAACCAGTA CTGGAGCGTG CGCCAGTCCA GGCGCACCGG 120 CGGCACCATC ACCACCGGCA ACCACTTCGA CGCCTGGGCC AGCCACGGCA TGAACCTGGG 180 CACCTTCAAC TACCAGATCC TGGCCACCGA RGGCTACCAA TSCTSCGGAA GCCG 234 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS8/6 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: AATTCGGCTT GACGGGGGRA CGTACGACAT CTACGAGCAC CAGCAAGTCA ACCAGCCCTC 60 CATCCAAGGC ACTGCGACCT TCAACCAGTA CTGGTCCATC CGCCAGAGCA AGCGTTCCAG 120 CGGCACTGTG ACCACTGCCA ACCACTTCAA TGCTTGGGCC AAGTTGGGAA TGAACCTGGG 180 CAACTTCAAC TACCAGATTG TTTCCACTGA RGGCTACCAG WCCTSCGGAA GCCG 234 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS8/11 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: AATTCGGCTT GACGGGGGGA CGTATGATAT CTACAAGCAC CAACAGGTCA ATCAGCCATC 60 TATTCAGGGC ACCGCCACCT TCAATCAGTA CTGGTCGATT CGACAGAGCA AGCGGACCAG 120 CGGCACTGTC ACTACGGCAA ACCACTTTAA TGCCTGGGCT GCTCTTGGCA TGAATATGGG 180 TGCATTCAAT TACCAGATCC TCGTTACTGA GGGCTACCAA TCTACCGGAA GCCG 234 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 213 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: NS8/12 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: AATTCGGCTT GACGGGGGGA CGTACGACAT TTATGAAACA ACCCGTGTCA ATCAGCCTTC 60 CATTATCGGG ATCGCAACCT TCAAGCAATA TTGGAGTGTA CGTCAAACGA AACGTACAAG 120 CGGAACGGTC TCCGTCAGTG CGCATTTTAG AAAATGGGAA AGCTTAGGGA TGCCAATGGG 180 GAAAATGTAT GAAACGGCAT TTACTGTAAG CCG 213 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM8A/1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50 : AATTCGGCTT TGGGACGTGG TGAATGAGGC AATGGCAGAC AATGTTCGTC CTAACCCGTG 60 GAATCCCAAC CCCTCGCCCT ACCGTGACTC CCGCCACTAC AAATTGTGCG GCGACGAGTT 120 CATCGCCAAG GCATTCCAAT TCGCAAGGGA AGCCGACCCG AAGGCACAAT TGTTCAACAA 180 CGACTACAAC AAGCCG 196 ( 2 ) INFORMATION FOR SEQ ID NO : 51 : ( i ) SEQUENCE CHARACTERISTICS : ( A ) LENGTH : 211 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM8A/3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: AATTCGGCTT GTTGTAGTCG TTGATGCACA GGACCGGGGC TTTGCCGTAC TTGGCGCAAG 60 CCTCTGTTGC ATAGGCGAAT GCAGCATCAA CCCAGTCTTT GGTGCTCGGG TAATAATTGC 120 CCCAAACAAA GTCGTTGGCA GATGCTCCCT GGGTGCGGAA TGCCCCGCCG GCACCGTCTG 180 CAAAGGTCTC GTTCACCACG TCCCAAAGCC G 211 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM8B/7 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: AATTCGGCTT GACGGGGGGA CGTACGACAT CTACAAGACC ACCAGATACG AACAGCCCTC 60 TATCGACGGC ACACAGACCT TCGACCAGTA CTGGAGCGTA AGACAGTCCA AGCCACAGGG 120 CGAGGGCAAG AAGATAGAAG GTACTATCTC AGTGTCCAAG CACTTCGATG CGTGGAAAAA 180 GTGCGGCCTT GAGCTCGGAA ATATGTATGA AGTANCTCTT ACTATCGAAG GGCTAAGCCG 240 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 229 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM8A/9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: AATTCCCGGA GGTTTGGCAG CCTTCAATAG TAAGAGCAGC TTCATACATT AATCCTAATT 60 TCATTCCTTT GCTTGTCCAA GCTTTGAAGT GGTCACTTAC AGAAATAGTT CCACTAGTTT 120 TTTTTTCAGT TCTGACACTC CAGAATTGTT TAAATGTAGC AGTACCATCA ATTGAAGGTT 180 GATTAATTCT GTCAGTGGTA TANATATCAT ACGTCCCCCC ATCAAGCCG 229 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: Hybrid DNA (vi) SCIENTIFIC NAME: KM8B/10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: AATTCGGCTT GACGGGGGGA CGTACGACAT ATACGAGACT ACTCGTTACA ACCAGCCTTC 60 AATCGAAGGC AACACTACTT TCCAGCAGTA CTGGAGCGTT CGTACATCCA AGCGCACCAG 120 CGGTACCATT TCCGTATCCG AGCACTTTAA GGCTTGGGAA CGCATGGGTA TGAGATGCGG 180 AAACCTTTAT GAGACTGCTT TAACTGTTGA GGGCTACCAN ACCACCGGAA GCCG 234 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iϋ) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Humicola insolens (B) STRAIN: DSM 1800 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 73..927 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 10..72 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 10..927 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: GGATCCAAG ATG CGT TCC TCC CCC CTC CTC CCG TCC GCC GTT GTG GCC 48 Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala -21 -20 -15 -10 GCC CTG CCG GTG TTG GCC CTT GCC GCT GAT GGC AGG TCC ACC CGC TAC 96 Ala Leu Pro Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr -5 1 5 TGG GAC TGC TGC AAG CCT TCG TGC GGC TGG GCC AAG AAG GCT CCC GTG 144 Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val 10 15 20 AAC CAG CCT GTC TTT TCC TGC AAC GCC AAC TTC CAG CGT ATC ACG GAC 192 Asn Gin Pro Val Phe Ser Cys Asn Ala Asn Phe Gin Arg He Thr Asp 25 30 35 40 TTC GAC GCC AAG TCC GGC TGC GAG CCG GGC GGT GTC GCC TAC TCG TGC 240 Phe Asp Ala Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys 45 50 55 GCC GAC CAG ACC CCA TGG GCT GTG AAC GAC GAC TTC GCG CTC GGT TTT 288 Ala Asp Gin Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe 60 65 70 GCT GCC ACC TCT ATT GCC GGC AGC AAT GAG GCG GGC TGG TGC TGC GCC 336 Ala Ala Thr Ser He Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala 75 80 85 TGC TAC GAG CTC ACC TTC ACA TCC GGT CCT GTT GCT GGC AAG AAG ATG 384 Cys Tyr Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met 90 95 100 GTC GTC CAG TCC ACC AGC ACT GGC GGT GAT CTT GGC AGC AAC CAC TTC 432 Val Val Gin Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe 105 110 115 120 GAT CTC AAC ATC CCC GGC GGC GGC GTC GGC ATC TTC GAC GGA TGC ACT 480 Asp Leu Asn He Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr 125 130 135 CCC CAG TTC GGC GGT CTG CCC GGC CAG CGC TAC GGC GGC ATC TCG TCC 528 Pro Gin Phe Gly Gly Leu Pro Gly Gin Arg Tyr Gly Gly He Ser Ser 140 145 150 CGC AAC GAG TGC GAT CGG TTC CCC GAC GCC CTC AAG CCC GGC TGC TAC 576 Arg Asn Glu Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr 155 160 165 TGG CGC TTC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC 624 Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe 170 175 180 CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC 672 Arg Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg 185 190 195 200 CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC 720 Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser 205 210 215 ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC 768 Thr Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr 220 225 230 TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC 816 Ser Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys 235 240 245 ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC 864 Thr Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys 250 255 260 ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC 912 Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr 265 270 275 280 CAT CAG TGC CTG TAGACGCAGG GCAGCTTGAG GGCCTTACTG GTGGCCGCAA 964 His Gin Cys Leu 285 CGAAATGACA CTCCCAATCA CTGTATTAGT TCTTGTACAT AATTTCGTCA TCCCTCCAGG 1024 GATTGTCACA TAAATGCAAT GAGGAACAAT GAGTAC 1060 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala Ala Leu Pro -21 -20 -15 -10 Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys -5 1 5 10 Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val Asn Gin Pro 15 20 25 Val Phe Ser Cys Asn Ala Asn Phe Gin Arg He Thr Asp Phe Asp Ala 30 35 40 Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys Ala Asp Gin 45 50 55 Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe Ala Ala Thr 60 65 70 75 Ser He Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala Cys Tyr Glu 80 85 90 Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Val Val Gin 95 100 105 Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Asn 110 115 120 He Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr Pro Gin Phe 125 130 135 Gly Gly Leu Pro Gly Gin Arg Tyr Gly Gly He Ser Ser Arg Asn Glu 140 145 150 155 Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr Trp Arg Phe 160 165 170 Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin Val 175 180 185 Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp 190 195 200 Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr Ser Ser 205 210 215 Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr 220 225 230 235 Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu 240 245 250 Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys 255 260 265 Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin Cys 270 275 280 Leu (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Conserved region" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: Thr Arg Tyr Trp Asp Cys Cys Lys Pro/Thr 1 5 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Conserved region" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: Trp Arg Phe/Tyr Asp Trp Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer s" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: GCTGATGGCA GGTCCACIA/CG ITAC/TTGGGAC/T TGC/TTGC/TAAA/GA/C C 41 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Primer as" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: GTCGGCGTTC TTA/GAACCAA/GT CA/GA/TAICG/TCC 29 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "forward primer 1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: TGGTTC/TAAGA ACGCCGACAA TCCG 24 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "reverse primer 1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: GCTCTAGAGC CTGCGTCTAC AGGCACTGAT 30 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 93 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "forward primer 2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: CGGGATCCCA TTTATGATGG TCGCGTGGTG GTCTCTATTT CTGTACGGCC TTCAGGTCGC GGCACCTGCT TTCGCTGCTG ATGGCAGGTC CAC 93 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc - "reverse primer 2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: GCTCTAGAGC CTGCGTCTAC AGGCACTGAT 30 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 922 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: hybrid DNA ( ix ) FEATURE : (A) NAME/KEY: CDS (B) LOCATION:1..922 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG 48 Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG CGG TAC TGG 96 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 GAT TGC TGT AAG CCG TCG TGC TCG TGG CCC GGC AAG GCG CTC GTG AAC 144 Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Leu Val Asn 35 40 45 CAG CCC GTC TAC GCC CGC AAC GCA AAC TTC CAG CGC ATC ACC GAC CCC 192 Gin Pro Val Tyr Ala Arg Asn Ala Asn Phe Gin Arg He Thr Asp Pro 50 55 60 AAC GCC AAG TCC GGC TGC GAT GGC GGC TCC GCC TTC TCC TGC GCC GAC 240 Asn Ala Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asp 65 70 75 80 CAG ACC CCG TGG GCC GTG AGC GAC GAC TTT GCC TAC GGT TTC GCG GCT 288 Gin Thr Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala 85 90 95 ACG GCG CTC GCC GGC CAG TCC GAG TCT TCG TGG TGC TGT GCC TGC TAC 336 Thr Ala Leu Ala Gly Gin Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr 100 105 110 GAA CTC ACC TTC ACT TCG GGC CCC GTT GCT GGC AAG AAG ATG GCT GTC 384 Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ala Val 115 120 125 CAG TCC ACC AGC ACT GGC GGT GAC CTC GGT AGC AAC CAC TTT GAC CTC 432 Gin Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu 130 135 140 AAC ATG CCA GGT GGC GGT GTC GGC ATC TTC GAC GGC TGC TCG CCT CAG 480 Asn Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Ser Pro Gin 145 150 155 160 GTT GGC GGT CTC GCC GGC CAG CGC TAT GGC GGC GTC TCG TCC CGC AGC 528 Val Gly Gly Leu Ala Gly Gin Arg Tyr Gly Gly Val Ser Ser Arg Ser 165 170 175 GAA TGC GAC TCC TTC CCC GCG GCA CTC AAG CCC GGC TGC TAC TGG CGC 576 Glu Cys Asp Ser Phe Pro Ala Ala Leu Lys Pro Gly Cys Tyr Trp Arg 180 185 190 TAC GAC TGG TTT AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT CAG 624 Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin 195 200 205 GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC AAC 672 Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn 210 215 220 GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC AGC 720 Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr Ser 225 230 235 240 TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC ACC 768 Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr 245 250 255 ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT GCT 816 Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala 260 265 270 GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGG TGC ACC ACC 864 Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr 275 280 285 TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT CAG 912 Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin 290 295 300 TGC CTG TAG A 922 Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Leu Val Asn 35 40 45 Gin Pro Val Tyr Ala Arg Asn Ala Asn Phe Gin Arg He Thr Asp Pro 50 55 60 Asn Ala Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asp 65 70 75 80 Gin Thr Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala 85 90 95 Thr Ala Leu Ala Gly Gin Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr 100 105 110 Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lye Lys Met Ala Val 115 120 125 Gin Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu 130 135 140 Asn Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Ser Pro Gin 145 150 155 160 Val Gly Gly Leu Ala Gly Gin Arg Tyr Gly Gly Val Ser Ser Arg Ser 165 170 175 Glu Cys Asp Ser Phe Pro Ala Ala Leu Lys Pro Gly Cys Tyr Trp Arg 180 185 190 Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin 195 200 205 Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn 210 215 220 Asp Asp Gly Asn Phe Pro Ala Val Gin He Pre Ser Ser Ser Thr Ser 225 230 235 240 Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr 245 250 255 Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala 260 265 270 Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr 275 280 285 Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin 290 295 300 Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 922 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATIONS..922 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: C CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT 46 Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu 1 5 10 15 CAG GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAC 94 Gin Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr 20 25 30 TGG GAT TGT TGT AAG CCC TCT TGC TCC TGG GGC GAC AAG GCC TCG GTC 142 Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Asp Lys Ala Ser Val 35 40 45 AGC GCC CCC GTC CTG ACC TGC GAC AAG AAC GAC AAC CCC ATC TCC GAC 190 Ser Ala Pro Val Leu Thr Cys Asp Lys Asn Asp Asn Pro He Ser Asp 50 55 60 GCC AAC GCC GTG AGC GGT TGC AAC GGC GGC ACT TCC TAC ACC TGC AGC 238 Ala Asn Ala Val Ser Gly Cys Asn Gly Gly Thr Ser Tyr Thr Cys Ser 65 70 75 AAC AAC TCC CCG TGG GCT GTC AAC GAC AAC CTC GCC TAT GGC TTT GCC 286 Asn Asn Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala 80 85 90 95 GCT ACC AAG CTC TCT GGA GGC TCC GAG TCC AGC TGG TGC TGT GCT TGC 334 Ala Thr Lys Leu Ser Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys 100 105 110 TAC GCT CTC ACC TTT ACG ACT GGC CCC GTG AAG GGC AAG ACC ATG GTC 382 Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val 115 120 125 GTA CAG TCC ACC AAC ACC GGA GGC GAT CTC GGC GAG AAC CAC TTC GAT 430 Val Gin Ser Thr Asn Thr Gly Gly Asp Leu Gly Glu Asn His Phe Asp 130 135 140 CTC CAG ATG CCC GGC GGC GGT GTC GGC ATC TTT GAC GGC TGC AGC TCC 478 Leu Gin Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Ser Ser 145 150 155 CAG TGG GGT GGC CTC GGC GGT GCT CAG TAC GGC GGC ATC TCG TCG CGA 526 Gin Trp Gly Gly Leu Gly Gly Ala Gin Tyr Gly Gly He Ser Ser Arg 160 165 170 175 AGC GAC TGC GAC AGC TTC CCC GAG CTG CTC AAG GAC GGC TGC TAC TGG 574 Ser Asp Cys Asp Ser Phe Pro Glu Leu Leu Lys Asp Gly Cys Tyr Trp 180 185 190 CGC TAC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT 622 Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg 195 200 205 CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC 670 Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg 210 215 220 AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC 718 Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr 225 230 235 AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC 766 Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser 240 245 250 255 ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT 814 Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr 260 265 270 GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC ACC 862 Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr 275 280 285 ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT 910 Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His 290 295 300 CAG TGC CTG TAG 922 Gin Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Asp Lys Ala Ser Val Ser 35 40 45 Ala Pro Val Leu Thr Cys Asp Lys Asn Asp Asn Pro He Ser Asp Ala 50 55 60 Asn Ala Val Ser Gly Cys Asn Gly Gly Thr Ser Tyr Thr Cys Ser Asn 65 70 75 80 Asn Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala 85 90 95 Thr Lys Leu Ser Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr 100 105 110 Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val Val 115 120 125 Gin Ser Thr Asn Thr Gly Gly Asp Leu Gly Glu Asn His Phe Asp Leu 130 135 140 Gin Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Ser Ser Gin 145 150 155 160 Trp Gly Gly Leu Gly Gly Ala Gin Tyr Gly Gly He Ser Ser Arg Ser 165 170 175 Asp Cys Asp Ser Phe Pro Glu Leu Leu Lys Asp Gly Cys Tyr Trp Arg 180 185 190 Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin 195 200 205 Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn 210 215 220 Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr Ser 225 230 235 240 Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr 245 250 255 Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala 260 265 270 Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr 275 280 285 Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin 290 295 300 Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 928 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..928 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG 48 Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAC TGG 96 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 GAT TGC TGC AAG CCC TCT TGC TCT TGG GGC GGA AAG GCT GCT GTC AGC 144 Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Gly Lys Ala Ala Val Ser 35 40 45 GCC CCT GCT TTG ACC TGT GAC AAG AAG GAC AAC CCC ATC TCA AAC CTG 192 Ala Pro Ala Leu Thr Cys Asp Lys Lys Asp Asn Pro He Ser Asn Leu 50 55 60 AAC GCT GTC AAC GGT TGT GAG GGT GGT GGT TCT GCC TTC GCC TGC ACC 240 Asn Ala Val Asn Gly Cys Glu Gly Gly Gly Ser Ala Phe Ala Cys Thr 65 70 75 80 AAC TAC TCT CCT TGG GCG GTC AAT GAC AAC CTT GCC TAC GGC TTC GCT 288 Asn Tyr Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala 85 90 95 GCA ACC AAG CTT GCC GGT GGC TCC GAG GGT AGC TGG TGC TGT GCT TGC 336 Ala Thr Lys Leu Ala Gly Gly Ser Glu Gly Ser Trp Cys Cys Ala Cys 100 105 110 TAC GCA CTT ACC TTC ACC ACC GGT CCC GTC AAG GGT AAG ACC ATG GTC 384 Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val 115 120 125 GTC CAG TCC ACC AAC ACT GGA GGC GAC CTC GGT GAC AAC CAC TTC GAT 432 Val Gin Ser Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp 130 135 140 CTT ATG ATG CCT GGT GGC GGT GTT GGA ATC TTC GAC GGT TGC ACT TCT 480 Leu Met Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr Ser 145 150 155 160 CAG TTC GGC AAG GCT CTC GGT GGT GCC CAG TAC GGT GGC ATC TCC TCC 528 Gin Phe Gly Lys Ala Leu Gly Gly Ala Gin Tyr Gly Gly He Ser Ser 165 170 175 CGA AGC GAG TGC GAC AGC TTC CCT GAG ACT CTC AAG GAC GGT TGC CAT 576 Arg Ser Glu Cys Asp Ser Phe Pro Glu Thr Leu Lys Asp Gly Cys His 180 185 190 TGG CGC TTC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC 624 Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe 195 200 205 CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC 672 Arg Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg 210 215 220 CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC 720 Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser 225 230 235 240 ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC 768 Thr Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr 245 250 255 TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC 816 Ser Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys 260 265 270 ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC 864 Thr Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys 275 280 285 ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC 912 Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr 290 295 300 CAT CAG TGC CTG TAG A 928 His Gin Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Gly Lys Ala Ala Val Ser 35 40 45 Ala Pro Ala Leu Thr Cys Asp Lys Lys Asp Asn Pro He Ser Asn Leu 50 55 60 Asn Ala Val Asn Gly Cys Glu Gly Gly Gly Ser Ala Phe Ala Cys Thr 65 70 75 80 Asn Tyr Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala 85 90 95 Ala Thr Lys Leu Ala Gly Gly Ser Glu Gly Ser Trp Cys Cys Ala Cys 100 105 110 Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val 115 120 125 Val Gin Ser Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp 130 135 140 Leu Met Met Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr Ser 145 150 155 160 Gin Phe Gly Lys Ala Leu Gly Gly Ala Gin Tyr Gly Gly He Ser Ser 165 170 175 Arg Ser Glu Cys Asp Ser Phe Pro Glu Thr Leu Lys Asp Gly Cys His 180 185 190 Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe 195 200 205 Arg Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg 210 215 220 Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser 225 230 235 240 Thr Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr 245 250 255 Ser Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys 260 265 270 Thr Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys 275 280 285 Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr 290 295 300 His Gin Cys Leu * (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 915 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..915 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG GTC GCG 48 Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin Val Ala 1 5 10 15 GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAT TGG GAT TGT 96 Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys 20 25 30 TGC AAG CCG TCA TGT GCT TGG TCC GGC AAG GCC TCA GTG TCA TCT CCC 144 Cys Lys Pro Ser Cys Ala Trp Ser Gly Lys Ala Ser Val Ser Ser Pro 35 40 45 GTG CGA ACC TGT GAC GCA AAC AAC TCG CCG CTG TCC GAC GTC GAC GCA 192 Val Arg Thr Cys Asp Ala Asn Asn Ser Pro Leu Ser Asp Val Asp Ala 50 55 60 AAG AGT GCG TGC GAT GGA GGC GTT GCT TAC ACT TGT TCA AAC AAC GCG 240 Lys Ser Ala Cys Asp Gly Gly Val Ala Tyr Thr Cys Ser Asn Asn Ala 65 70 75 80 CCT TGG GCT GTT AAC GAT AAC CTC TCT TAT GGT TTC GCG GCC ACA GCT 288 Pro Trp Ala Val Asn Asp Asn Leu Ser Tyr Gly Phe Ala Ala Thr Ala 85 90 95 ATC AAT GGC GGC AGC GAG TCT AGC TGG TGC TGT GCA TGC TAC AAG TTG 336 He Asn Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr Lys Leu 100 105 110 ACT TTC ACG AGC GGA CCT GCT TCT GGA AAG GTC ATG GTC GTT CAA TCA 384 Thr Phe Thr Ser Gly Pro Ala Ser Gly Lys Val Met Val Val Gin Ser 115 120 125 ACC AAC ACC GGG TAC GAT CTC TCT AAC AAC CAC TTT GAC ATT CTT ATG 432 Thr Asn Thr Gly Tyr Asp Leu Ser Asn Asn His Phe Asp He Leu Met 130 135 140 CCA GGT GGC GGT GTT GGA GCG TTC GAC GGC TGC TCT AGG CAG TAC GGC 480 Pro Gly Gly Gly Val Gly Ala Phe Asp Gly Cys Ser Arg Gin Tyr Gly 145 150 155 160 AGC ATC CCT GGG GAG CGA TAT GGG GGT GTC ACA TCA AGG GAC CAA TGC 528 Ser He Pro Gly Glu Arg Tyr Gly Gly Val Thr Ser Arg Asp Gin Cys 165 170 175 GAC CAA ATG CCA AGT GCA CTC AAG CAG GGC TGC TAT TGG CGC TTC GAT 576 Asp Gin Met Pro Ser Ala Leu Lys Gin Gly Cys Tyr Trp Arg Phe Asp 180 185 190 TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT CAG GTC CAG 624 Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin Val Gin 195 200 205 TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC AAC GAC GAC 672 Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp Asp 210 215 220 GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC AGC TCT CCG 720 Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr Ser Ser Pro 225 230 235 240 GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC ACC ACC TCG 768 Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr Ser 245 250 255 AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT GCT GAG AGG 816 Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu Arg 260 265 270 TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC ACC ACC TGC GTC 864 Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys Val 275 280 285 GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT CAG TGC CTG 912 Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin Cys Leu 290 295 300 TAG 915 * 305 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin Val Ala 1 5 10 15 Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys 20 25 30 Cys Lys Pro Ser Cys Ala Trp Ser Gly Lys Ala Ser Val Ser Ser Pro 35 40 45 Val Arg Thr Cys Asp Ala Asn Asn Ser Pro Leu Ser Asp Val Asp Ala 50 55 60 Lys Ser Ala Cys Asp Gly Gly Val Ala Tyr Thr Cys Ser Asn Asn Ala 65 70 75 80 Pro Trp Ala Val Asn Asp Asn Leu Ser Tyr Gly Phe Ala Ala Thr Ala 85 90 95 He Asn Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr Lys Leu 100 105 110 Thr Phe Thr Ser Gly Pro Ala Ser Gly Lys Val Met Val Val Gin Ser 115 120 125 Thr Asn Thr Gly Tyr Asp Leu Ser Asn Asn His Phe Asp He Leu Met 130 135 140 Pro Gly Gly Gly Val Gly Ala Phe Asp Gly Cys Ser Arg Gin Tyr Gly 145 150 155 160 Ser He Pro Gly Glu Arg Tyr Gly Gly Val Thr Ser Arg Asp Gin Cys 165 170 175 Asp Gin Met Pro Ser Ala Leu Lys Gin Gly Cys Tyr Trp Arg Phe Asp 180 185 190 Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gin Val Gin 195 200 205 Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp Asp 210 215 220 Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr Ser Ser Pro 225 230 235 240 Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr Ser 245 250 255 Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu Arg 260 265 270 Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys Val 275 280 285 Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His Gin Cys Leu 290 295 300 305 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 925 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATIONS..925 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: C CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT 46 Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu 1 5 10 15 CAG GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG CGG TAT 94 Gin Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr 20 25 30 TGG GAT TGC TGT AAG CCC AGC TGC TCC TGG CCC GAC AAG GCC CCC GTA 142 Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Asp Lys Ala Pro Val 35 40 45 GGT TCC CCC GTA GGC ACC TGC GAC GCC GGC AAC AGC CCC CTC GGC GAC 190 Gly Ser Pro Val Gly Thr Cys Asp Ala Gly Asn Ser Pro Leu Gly Asp 50 55 60 CCC CTG GCC AAG TCT GGC TGC GAG GGC GGC CCG TCG TAC ACG TGC GCC 238 Pro Leu Ala Lys Ser Gly Cys Glu Gly Gly Pro Ser Tyr Thr Cys Ala 65 70 75 AAC TAC CAG CCG TGG GCG GTC AAC GAC CAG CTG GCC TAC GGC TTC GCG 286 Asn Tyr Gin Pro Trp Ala Val Asn Asp Gin Leu Ala Tyr Gly Phe Ala 80 85 90 95 GCC ACG GCC ATC AAC GGC GGC ACC GAG GAC TCG TGG TGC TGC GCC TGC 334 Ala Thr Ala He Asn Gly Gly Thr Glu Asp Ser Trp Cys Cys Ala Cys 100 105 110 TAC AAG CTC ACC TTC ACC GAC GGC CCG GCC TCG GGC AAG ACC ATG ATC 382 Tyr Lys Leu Thr Phe Thr Asp Gly Pro Ala Ser Gly Lys Thr Met He 115 120 125 GTC CAG TCC ACC AAC ACG GGC GGC GAC CTG TCC GAC AAC CAC TTC GAC 430 Val Gin Ser Thr Asn Thr Gly Gly Asp Leu Ser Asp Asn His Phe Asp 130 135 140 CTG CTC ATC CCC GGC GGC GGC GTC GGC ATC TTC GAC GGC TGC ACC TCC 478 Leu Leu He Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr Ser 145 150 155 CAG TAC GGC CAG GCC CTG CCC GGC GCC CAG TAC GGC GGC GTC AGC TCC 526 Gin Tyr Gly Gin Ala Leu Pro Gly Ala Gin Tyr Gly Gly Val Ser Ser 160 165 170 175 CGC GCC GAG TGC GAC CAG ATG CCC GAG GCC ATC AAG GCC GGC TGC CAG 574 Arg Ala Glu Cys Asp Gin Met Pro Glu Ala He Lys Ala Gly Cys Gin 180 185 190 TGG CGC TAC GAT TGG TTT AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC 622 Trp Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe 195 200 205 CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC 670 Arg Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg 210 215 220 CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC 718 Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser 225 230 235 ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC 766 Thr Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr 240 245 250 255 TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC 814 Ser Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys 260 265 270 ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC 862 Thr Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys 275 280 285 ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC 910 Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr 290 295 300 CAT CAG TGC CTG TAG 925 His Gin Cys Leu * 305 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gin 1 5 10 15 Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp 20 25 30 Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Asp Lys Ala Pro Val Gly 35 40 45 Ser Pro Val Gly Thr Cys Asp Ala Gly Asn Ser Pro Leu Gly Asp Pro 50 55 60 Leu Ala Lys Ser Gly Cys Glu Gly Gly Pro Ser Tyr Thr Cys Ala Asn 65 70 75 80 Tyr Gin Pro Trp Ala Val Asn Asp Gin Leu Ala Tyr Gly Phe Ala Ala 85 90 95 Thr Ala He Asn Gly Gly Thr Glu Aβp Ser Trp Cys Cys Ala Cys Tyr 100 105 110 Lys Leu Thr Phe Thr Asp Gly Pro Ala Ser Gly Lys Thr Met He Val 115 120 125 Gin Ser Thr Asn Thr Gly Gly Asp Leu Ser Asp Asn His Phe Asp Leu 130 135 140 Leu He Pro Gly Gly Gly Val Gly He Phe Asp Gly Cys Thr Ser Gin 145 150 155 160 Tyr Gly Gin Ala Leu Pro Gly Ala Gin Tyr Gly Gly Val Ser Ser Arg 165 170 175 Ala Glu Cys Asp Gin Met Pro Glu Ala He Lys Ala Gly Cys Gin Trp 180 185 190 Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg 195 200 205 Gin Val Gin Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg 210 215 220 Asn Asp Asp Gly Asn Phe Pro Ala Val Gin He Pro Ser Ser Ser Thr 225 230 235 240 Ser Ser Pro Val Asn Gin Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser 245 250 255 Thr Thr Ser Ser Pro Pro Val Gin Pro Thr Thr Pro Ser Gly Cys Thr 260 265 270 Ala Glu Arg Trp Ala Gin Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr 275 280 285 Thr Cys Val Ala Gly Ser Thr Cys Thr Lys He Asn Asp Trp Tyr His 290 295 300 Gin Cys Leu * 305

Claims: PATENT CLAIMS 1. A method for providing a novel DNA sequence encoding a polypeptide from a micro-organism with an activity of interest comprises the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of i nterest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv) 2. The method according to claim 1 wherein the PCR primers in step i) have homology to conserved regions in (a) known structural gene(s) or the polypeptide(s) thereof. 3. The method according to claim 1 wherein the PCR primers in step i) are degenerated on the basis of conserved regions in (a) known gene(s) . 4. The method according to any of claims l to 3 wherein the PCR amplification in step i) is performed using naturally occurring DNA as template. 5. The method according to any of claims 1 to 3 wherein the microorganism has not been subjected to "in vitro" selection. 6. The method according to any of claims 1 to 5 wherein the PCR amplification in step i) is performed on a sample containing DNA from an un-isolated microorganism. 7. The method according to any of claims l to 6 wherein the 5' and 3 ' structural gene sequences originate from two different structural genes encoding polypeptides having the same activity. 8. The method according to any of claims 1 to 7 wherein the 5' structural gene sequence and the 3• structural gene sequence originate from the same structural gene sequence. 9. The method according to any of claims l to 8 wherein the 5' structural gene sequence and the 3* structural gene sequence originate from two different structural gene sequences encoding polypeptides having different activities. 10. The method according to any of claims l to 9 comprising the following steps: i) PCR amplification of DNA from micro-organisms with PCR primers being homologous to conserved regions of a known gene encoding a polypeptide with an activity of interest, ii) cloning the obtained PCR product into a gene encoding a polypeptide having the activity of interest, where said gene is not identical to the gene from which the PCR product is obtained, which gene is situated in an expression vector, iii) transforming said expression vector into a suitable host cell, iiia) culturing said host cell under suitable conditions, iv) screening for clones comprising a DNA sequence originated from the PCR amplification in step i) encoding a polypeptide with said activity of interest or related activity, v) isolating the DNA sequence identified in step iv) . 11. The method according to claims l to 10, wherein the micro¬ organism from which DNA is to be PCR amplified in step i) is a prokaryote or an eukaryote. 12. The method according to any of claims 1 to 11, wherein the PCR amplification in step i) is performed on DNA from an un- cultivable organism. 13. The method according to claim 12, wherein the un-cultivable organism is an algae, a fungi or a protozoa. 14. The method according to claims 12 and 13, wherein said un- cultivable organism is from the group of extremophiles and plantonic marine organisms. 15. The method according to any of claims 1 to 11, wherein the PCR amplification in step i) is performed on DNA from a cultivable organism. 16. The method according to claim 15, wherein said cultivable organism is selected from the group of bacteria, fungal organisms, such as filamentous fungi or yeasts. 17. The method according to claim 16, wherein said PCR amplifica¬ tion in step i) is performed on one or more polynucleotides comprised in a vector, plasmid or the like, such as on a cDNA library from cultivable organisms. 18. The method according any of claims 1 to 17, wherein said activity of interest is an enzymatic activity. 19. The method according to claim 18, wherein said enzyme activity is selected from the group comprising phosphatases oxidoreductases, transferases, hydrolases, such as esterases , in particular lipases and phytases, such as glucosidases, in particular xylanases, cellulases, hemicellulases, and amylases, such as peptidases, in particular proteases, lyases, isomerases and ligases. 20. The method according to any of claims 10 to 19, wherein said host cell mentioned under iii) of claim 10 is a micro-organism, preferably a yeast or a bacteria. 21. The method according to claim 20, wherein said host cell is a yeast such as a strain of Saccharomyces, in particular Saccharomyces cerevisiae. 22. The method according to claim 20, wherein said host cell is a bacteria such as a strain of Bacillus , in particular of Bacillus subtilis, or a strain Escherichia coli . 23. The method according to any of claims 1 to 22, wherein the clones/hybrid DNA sequences mentioned in step iv) , are screened for enzymatic activity. 24. The method according to claim 23, wherein the screened clones/hybrid DNA sequences are tested for wash performance. 25. A novel DNA sequence provided according to any of the method claims 1 to 24. 26. A polypeptide with an activity of interest encoded by a DNA sequence of claim 25.

Inventors: DALBOEGE HENRIK, DIDERICHSEN BOERGE, KAUPPINEN SAKARI, SANDAL THOMAS, DALBOEGE, HENRIK, DIDERICHSEN, BOERGE, KAUPPINEN, SAKARI, SANDAL, THOMAS
Applicants: DALBOEGE HENRIK, DIDERICHSEN BOERGE, KAUPPINEN SAKARI, NOVONORDISK AS, SANDAL THOMAS, DALBOEGE, HENRIK, DIDERICHSEN, BOERGE, KAUPPINEN, SAKARI, NOVO NORDISK A/S, SANDAL, THOMAS
Application year: 1997
Main classification: C12N15
IPC codes: C12N9, C12N15, C12Q1